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please cT he challenges inherent in conducting accurate, clin-ically effective, and cost-effective cardiac evalua-tions among transplantation candidates relate to the
arge size of the target population, the prevalence of disease,
he limited number of donated organs, and the often extended
aiting periods between initial evaluation and transplantation
urgery. According to Organ Procurement and Transplant
etwork (OPTN) records, nearly 85,000 candidates were on
he waiting list for kidney transplantation in 2010, and
17,700 kidney transplantations (including 828 kidney-
ancreas transplantations) were performed (1). Also in 2010,
6,000 people were awaiting liver transplantation and 6,000
eceived liver allografts (1). Marked shifts in the age compo-
ition of transplant waitlists toward older adults are also
aising the average medical complexity and comorbidity
urden among listed candidates. In 2011, 62% of kidney
ransplantation candidates were 50 years of age compared
ith 28.7% of kidney transplantation candidates in 1991 (1).
similar shift in age distribution has occurred among liver
ransplantation candidates; now, 77% are 50 years of age
1). Cardiovascular disease is a leading cause of morbidity
nd mortality among patients with end-stage failure of non-
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uggest particularly high frequencies of cardiovascular
vents in the first months after kidney transplantation
2,4,5). Cardiovascular diseases in aggregate make up the
ost common cause of death in patients with functioning
llografts at all times after kidney transplantation, account-
ng for 30% of mortality overall, with highest rates in the
eritransplantation period (6).
Guidelines and position papers by national organizations
an serve as useful tools for informing cardiac evaluation
ractices before noncardiac surgery. However, the discrepan-
ies among existing guidelines and the unique clinical char-
cteristics of patients with end-stage organ failure raise
uestions about the applicability of available recommenda-
ions to transplantation candidates. In 2007, the American
ollege of Cardiology (ACC) and American Heart Associa-
ion (AHA) issued their most recent version of the “Guide-
ines on Perioperative Cardiovascular Evaluation and Care
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July 31, 2012:434–80 Cardiac Disease Evaluation and Management Among Transplantation Candidatesr Noncardiac Surgery” (7). The algorithm suggests consid-
ation of further cardiac evaluation in symptomatic patients
t does not encourage further testing for patients who have
cardiac symptoms with a functional capacity of 4
etabolic equivalent tasks (METS; i.e, ability to climb a
ight of stairs), regardless of diabetic status, history of
ronary artery disease (CAD), or other traditional cardiac
sk factors. Consideration of noninvasive testing was given a
lass IIb recommendation in asymptomatic patients with at
ast 1 to 2 clinical risk markers and poor functional capacity
ho require intermediate-risk noncardiac surgery if it will
ange management (Level of Evidence B), with the evi-
nce grade reflecting lack of large randomized trials to
pport this strategy (Table 1). Similarly, the “2009 Appro-
iate Use Criteria for Cardiac Radionuclide Imaging” (8) by
e American College of Cardiology Foundation (ACCF),
ong with key specialty and subspecialty societies, deemed
at radionuclide imaging is appropriate for perioperative
aluation before intermediate-risk noncardiac surgery in
ymptomatic patients only when at least 1 risk marker in
esent and the patient has poor (4 METS) or unknown
nctional capacity (8). The ACC/AHA and ACCF guidelines
ere not written specifically for patients with end-stage organ
ilure, and the predictive value of the “absence of cardiac
mptoms” may differ in transplantation candidates compared
ith the general population. These guidelines also take the
rspective that noncardiac surgery will be performed shortly
ter the evaluation and that any management decisions will
fect short-term (perioperative) outcomes. In contrast, cardiac
aluation and interventions in transplantation candidates should
ble 1. Evidence Grading
idence Class: Magnitude of procedure/treatment effect
I Conditions for which there is evidence for and/or general
agreement that the procedure/therapy is useful and
effective
II Conditions for which there is conflicting evidence and/or
a divergence of opinion about the usefulness/efficacy of
performing the procedure/therapy
IIa Weight of evidence/opinion is in favor of usefulness/
efficacy
IIb Usefulness/efficacy is less well established by evidence/
opinion
III Conditions for which there is evidence and/or general
agreement that the procedure/therapy is not
useful/effective and in some cases may be harmful
idence Level: Estimate of certainty (precision) of procedure/treatment
fect*
A Consistent direction and magnitude of effect from
multiple randomized controlled clinical trials
B Consistent retrospective cohort, exploratory cohort,
ecological, outcomes research, or case-control studies,
or extrapolations from Level A studies
C Case-series studies or extrapolations from Level B
studies
*A recommendation with Level of Evidence B or C does not imply that the
commendation is weak. Although randomized trials are not available, there
ay be a very clear consensus that a particular test or therapy is effective.considered from both the short- and long-term perspective. teThe fundamental basis of the latest ACC/AHA recommen-
tions is grounded in understanding of the role of coronary
vascularization before noncardiac surgery. The authors
ate, “Patients with asymptomatic ischemia. . .do not appear
be candidates for prophylactic preoperative coronary re-
scularization unless cardiac catheterization reveals high-
sk surgical anatomy” (7). This statement is supported by 2
cent randomized trials that did not demonstrate benefit of
rcutaneous coronary intervention (PCI) or coronary artery
pass grafting (CABG) for revascularization of asymptom-
ic CAD before major vascular surgery (9–11).
In 2005, the National Kidney Foundation published the
linical Practice Guidelines for Cardiovascular Disease in
ialysis Patients” within the Kidney Disease Outcomes
uality Initiative (NKF/KDOQI) (12). The section on CAD
ggests more aggressive screening of patients with end-stage
nal disease (ESRD) as part of the evaluation to determine
ndidacy for renal transplantation than would be suggested
ACC/AHA guidelines, although the statements were rated
evel of Evidence C, this is, based on either weak evidence
the opinions of the working group. For example, this
gorithm recommends that any patient on the kidney trans-
ant waitlist with a history of diabetes mellitus or known
AD undergo noninvasive stress testing at baseline and then
bsequently every 12 months until transplantation. There is
similar recommendation for transplantation candidates
emed at high risk per Framingham criteria (2 traditional
sk factors, left ventricular ejection fraction [LVEF] 40%,
peripheral vascular disease) (12).
Other consensus-based recommendations for cardiac risk
sessment before kidney transplantation have been offered.
hese include a 2007 report from an international collabora-
on of the NKF and the Transplantation Society called the
isbon Conference (13), the 2001 American Society of
ransplantation (AST) guidelines (14), and the 2000 Euro-
an Renal Association-European Dialysis Transplant Asso-
ation (ERA-EDTA) “European Best Practice Guidelines” (15).
hese 2 clinical practice guidelines are now10 years old, were
sed on expert consensus panels, and were not the product of
stematic review of the evidence. Although all these documents
ggest that symptomatic patients should undergo further test-
g, they offer differing recommendations for asymptomatic
tients. A comparison of these 5 clinical documents and their
commendations on testing asymptomatic patients for CAD
fore renal transplantation is summarized in Table 2.
Several studies document heterogeneity in cardiac evalua-
on practices before kidney transplantation at the national
vel (Table 3). In a 1993 survey of directors of OPTN-
rticipating centers, noninvasive stress testing was reported
the most common first approach to cardiac evaluation of
ymptomatic patients, prompted by diabetes mellitus at 86%
responding centers, age (mean threshold, 52 years) at 67%,
d multiple risk factors at 68% (18). Some centers used
utine coronary angiography for patients with diabetes
ellitus (15%), older age (7%; mean threshold, 57 years), or
ultiple risk factors (8%). A subsequent survey of OPTN
nters about policies for patients on the deceased donor
aiting list found that 8% of programs reported cardiac
sting for all candidates, whereas 18% did not routinely
or
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Cardiac Disease Evaluation and Management Among Transplantation Candidates July 31, 2012:434–80der cardiac testing for any asymptomatic patient group;
% screened patients with diabetes mellitus, 52% screened
tients with a history of CAD, and 52% screened patients
emed to be high risk for cardiac events after transplantation
ven their age or obesity (19). Methods of screening were
so variable: 40% pharmacological-nuclear, 33% exercise
clear, 31% dobutamine stress echocardiography (DSE),
d 15% cardiac catheterization. Cardiac surveillance poli-
es among listed candidates also differ across centers. In a
rvey of 68 centers in 2005, 51% of program representatives
dicated reliance on the initial cardiac evaluation and cardiac
story, 7% used ACC/AHA criteria for noncardiac surgery in
e general population to guide cardiac revaluation, and 32%
plied a combination of ACC/AHA criteria, the initial
ble 2. Published Recommendations for Testing for CAD in Asy
Reference
12 AHA Scientific
atement
Noninvasive stress testing may be considered in kidn
of the presence of multiple CAD risk factors regardles
Relevant risk factors among transplantation candidate
LV hypertrophy, age 60 y, smoking, hypertension, a
prompt testing remains to be determined, but the com
07 ACC/AHA
rioperative
idelines for
ncardiac
rgery (7)
No testing recommended if functional status 4 MET
If functional status 4 METS or unknown, then cons
clinical risk factors
Ischemic heart disease
Compensated or prior heart failure
Diabetes mellitus
Renal insufficiency
Cerebrovascular disease
Recommendations for testing are stronger if 3 clini
07 Lisbon
nference (13)
Acknowledges that there are no data establishing tha
noninvasive and/or invasive testing should be conside
Diabetes mellitus
Prior cardiovascular disease
Multiple cardiac risk factors such as 1 y on dialy
Does not specify the number of risk factors to justify
05 NKF/KDOQI
idelines (12)
Noninvasive stress testing recommended for
All patients with diabetes; repeat every 12 mo
All patients with prior CAD
If not revascularized, repeat every 12 mo
If prior PCI, repeat every 12 mo
If prior CABG, repeat after first 3 y and then eve
Repeat every 24 mo in “high-risk” nondiabetic pat
2 traditional risk factors
Known history of CAD
LVEF 40%
Peripheral vascular disease
01 AST
idelines (16)
Noninvasive stress testing recommended for patients
ischemic heart disease, or 2 risk factors
Coronary angiography for possible revascularization b
Revascularization before transplantation recommende
00 European
st Practice
idelines (15)
Thallium scanning recommended for patients with his
Coronary angiography recommended if thallium scann
Revascularization advised if lesions are suitable
ACC indicates American College of Cardiology; AHA, American Heart Associatio
D, coronary artery disease; KDOQI, Kidney Disease Outcomes Quality Initiative;
sks; and PCI, percutaneous coronary intervention.rdiac evaluation, and cardiac history (20). wSurvey responses are limited by nonresponse rates, and
ported policies may differ from actual practices. A retro-
ective study of the U.S. Renal Data System (USRDS)
gistry used billing claims as measures of cardiac evaluation
rvices in Medicare beneficiaries transplanted in 1991 to
04 (21). Forty-six percent of the sample received noninva-
ve stress testing or angiography at some time before
ansplantation (65% of high risk, defined as diabetes melli-
s, prior ischemic heart disease, or 2 other coronary risk
ctors, and 20% of lower risk). There was substantial
terogeneity in cardiac evaluation frequency according to
tient-level factors even within risk groups. After adjust-
ent for patient traits and consistent within risk profile–
ratified samples, transplantation without cardiac evaluation
atic Kidney Transplantation Candidates
commendations
plantation candidates with no active cardiac conditions on the basis
ctional status (Class IIb, Level of Evidence C)
e diabetes mellitus, prior cardiovascular disease, 1 y on dialysis,
ipidemia; the specific number of risk factors that should be used to
considers 3 to be reasonable
of noninvasive stress testing is recommended based on the following
factors are present but may be considered in those with 1–2 risk factors
ing of asymptomatic patients in itself prevents cardiac events;
ighest-risk patients with the following conditions
hypertrophy, age 60 y, smoking, hypertension, and dyslipidemia
o
fined as
risk,” defined as renal disease from diabetes, prior history of
nsplantation recommended for patients with a positive stress test
tients with critical coronary lesions
myocardial infarction or “high-risk” clinical features
ositive
American Society of Transplantation; CABG, coronary artery bypass grafting;
entricular; LVEF, left ventricular ejection fraction; METS, metabolic equivalentmptom
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July 31, 2012:434–80 Cardiac Disease Evaluation and Management Among Transplantation Candidatesrtain geographic regions. Race-related practice variables
ere notable because in the lower-risk group transplanted
ithout cardiac evaluation, black patients faced higher risks
post-transplantation MI than nonblack patients. Black race
s previously been identified as an independent predictor of
ilure to complete the pretransplantation evaluation (22) and
reduced access to coronary angiography and revascular-
ation in populations without kidney disease (23). Thus,
me of the observed practice variation may reflect access
rriers rather than appropriate determinations of low clinical
sk. An important limitation of studies based on billing data,
wever, is that claims may not distinguish screening tests
om tests performed because of cardiac symptoms.
A recent single-center study examined the approach to the
ymptomatic kidney transplantation candidate, which de-
nes the majority of potential candidates at the time of
ferral (24). In this study, medical charts were reviewed to
antify the hypothetical frequency of recommended testing
r practice recommendations and the observed results of
rdiac testing (primarily DSE or myocardial perfusion scin-
graphy [MPS]) among 204 consecutive patients who were
termined to be free of an active cardiac condition by a
rdiologist at the time of transplantation evaluation. Active
rdiac conditions were defined according to the ACC/AHA
finition including significant valvular disease, decompen-
ted heart failure, significant arrhythmias, and unstable
ronary syndromes. If followed precisely, the ACC/AHA
idelines recommended testing in only 20% of patients,
ble 3. Summary of Survey and Registry Data Demonstrating V
S. Transplantation Centers
Authors, Year
mos et al. (18), 1994 1993 survey of directors of UNOS-participati
(147 of 182)
Noninvasive stress testing was reported as t
prompted by diabetes mellitus at 86% of res
at 68%
A notable minority of centers espoused first-
mean threshold, 57 y), or multiple risk facto
novitch et al. (19), 2002 2001 survey of UNOS-participating centers r
67% final response rate (192 of 287)
8% of programs reported cardiac testing for
asymptomatic patient group
rifian et al. (20), 2006 2005 survey of U.S. kidney transplantation c
waiting list
26% final response rate (68 of 257)
51% of respondents indicated reliance on th
stated that AHA criteria were used to guide
cardiac evaluation, and cardiac history
ntine et al. (21), 2008 Retrospective study of pretransplantation car
1991–2004
Pretransplantation cardiac evaluation testing
Clinical traits defining “high” expected IHD r
or 2 other CAD risk factors
46.3% (65.4% of high-risk and 20.4% of low
the adjusted odds of transplantation without
duration, and also correlated with black race
Overall, 9.5% who received cardiac evaluatio
0.3% of lower-risk patients undergoing card
AHA indicates American Heart Association; CAD, coronary artery disease; IHDhereas the KDOQI guidelines would have resulted in 100% sepatients being tested. Among the 178 patients who under-
ent stress tests, the prevalence of ischemia was similar
ong those for whom testing was and was not recom-
ended per the ACC/AHA guidelines, 10.3% versus 9.4%,
spectively. The relatively low use of coronary revascular-
ation after pretransplantation cardiac evaluation also raises
ncern for the clinical and cost-effectiveness of pretrans-
antation cardiac evaluation as applied. Several registry-
sed and single-center observational studies have found that
ly 2.9% to 9.5% of patients who receive pretransplantation
rdiac stress testing or angiography proceeded to angio-
asty or surgical bypass (21,25–28).
Given the variation between practice and prior guidelines
patients being evaluated for solid-organ transplantation, it
important to determine whether evidence can resolve the
sis of this difference. The role for stress testing in the
sence of symptoms has been called into question among
tients undergoing noncardiac surgery because randomized
udies of coronary revascularization before vascular surgery
ve failed to show a consistent benefit (9–11). Outside the
rioperative setting, PCI has failed to demonstrate benefit
r the risk of major adverse cardiovascular events (MACEs)
a randomized trial among stable patients with CAD (29),
cluding a subgroup with chronic kidney disease (CKD) at
ial enrollment (30). Evidence suggests that the only asymp-
matic patients in whom coronary revascularization may be
lpful are the minority found to have occult high-risk
ronary anatomy such as significant left main disease or
n in Cardiac Evaluation Practices Across
Summary
rs regarding practices for initial candidate evaluations; 81% response rate
common first approach to cardiac evaluation of asymptomatic patients,
centers, age (mean threshold 52 y) at 67%, and multiple risk factors
iography for patients with diabetes mellitus (15%), older age (7%;
management practices for patients on the deceased donor waiting list
d candidates, whereas 18% did not order routine cardiac testing for any
egarding reevaluation practices for patients on the deceased donor
cardiac evaluation and cardiac history; 7% of program representatives
revaluation; and 32% espoused a combination of AHA criteria, the initial
luation practices among 27,786 Medicare beneficiaries transplanted in
ntified by billing claims for noninvasive stress tests and angiography
defined by AST guidelines (16) as diabetes mellitus, prior IHD,
patients) underwent cardiac evaluation testing before transplantation;
evaluation testing increased sharply with younger age and shorter dialysis
sex, and certain geographic regions
g also received pretransplantation revascularization, but only
ation testing were revascularized before transplantation
ic heart disease; and UNOS, United Network for Organ Sharing.ariatio
ng cente
he most
ponding
line ang
rs (8%)
egarding
all liste
enters r
e initial
cardiac
diac eva
was ide
isk were
er-risk
cardiac
, female
n testin
iac evaluvere proximal 3-vessel disease, especially in the presence
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Cardiac Disease Evaluation and Management Among Transplantation Candidates July 31, 2012:434–80reduced left ventricular systolic function (31,31a). How-
er, noninvasive cardiac testing of transplantation candi-
tes might yield findings that call into question the appro-
iateness of transplantation or identify high-risk coronary
sions associated with long-term benefit from revasculariza-
on. This report evaluates the state of evidence regarding
rdiac risk evaluation and management in kidney transplan-
tion and liver transplantation candidates, considering data
ecific to these populations and the appropriateness of
trapolations when data from these populations are lacking.
his article focuses on cardiac disease; issues related specif-
ally to the evaluation of carotid or peripheral vascular
sease are beyond the scope of this document.
ethodology and Evidence
he AHA Writing Committee on Cardiac Disease Evaluation
d Management Among Kidney and Liver Transplantation
andidates conducted a comprehensive review of the litera-
re relevant to perioperative cardiac evaluation of potential
dney or liver transplant recipients, including the prevalence
CAD in these populations; incidence of MACEs before
d after transplantation; accuracy of clinical risk markers,
mptoms, and noninvasive testing before and after transplant
sting for detecting active cardiac conditions and CAD; and
inical outcomes of revascularization and the medical man-
ement of atherosclerosis. Each section was assigned to a
ad author and coauthor. Literature searches were conducted
the following databases: PubMed, MEDLINE, and the
ochrane Library (including the Cochrane Database of Sys-
matic Reviews and the Cochrane Controlled Trials Regis-
r). Searches were limited to the English language, the years
90 through March 2010, and human subjects. Related-
ticle searches were conducted in MEDLINE to find addi-
onal relevant articles. Finally, committee members recom-
ended applicable articles outside the scope of the formal
arches. Interval drafts were discussed during conference
lls and 2 face-to-face meetings. Recommendations included
evaluation of the strength of the evidence for or against a
rticular procedure or treatment in terms of the magnitude of
fect (evidence class) and estimate of certainty (evidence
vel) (Table 1). Recommendations were subjected to formal,
onymous voting. The volume of text devoted to cardiac
aluation and management issues for kidney and liver
ansplantation candidates, respectively, reflects the relative
zes of the target populations; the number of patients
aiting and receiving kidney transplants is 4 times the
mber of patients awaiting and receiving liver allografts.
orrespondingly, a substantially larger number of publica-
ons with liver transplantation candidates.
hat Are the Goals of
reoperative Cardiac Risk Evaluation
Transplantation Candidates?
he most compelling goal of preoperative cardiac risk eval-
tion is to reduce the morbidity and mortality of cardiovas-
lar disease. Any test used to screen a population is rusociated with false-positive and -negative results that may
minish utility. False-positive results in particular may lead
patient and physician anxiety and the possibility of
ditional and often unnecessary testing or invasive proce-
res. Screening asymptomatic patients should be used only
the benefits of screening outweigh the harms. In asymp-
matic patients, screening for CAD would be of value if the
sults of testing lead to management changes that reduce the
currence of patient-level outcomes. Screening should also
cost-effective. For organ transplantation, cardiac evalua-
on could also be used to deny transplantation to high-risk
tients, provided that it can be shown that patients with
vere cardiovascular disease have sufficiently short life
pectancy to make transplantation a poor use of scarce
nated organs. However, studies have shown that survival is
nerally improved by transplantation compared with re-
aining on the transplant waiting list, even among high-risk
tients (32–34). Thus, the burden of proof in using screening
determine transplantation candidacy from a patient-centered
rspective is to demonstrate that denying transplantation on the
sis of test results is in the best interest of the patient.
lternatively, society may decide that cardiovascular evaluation
sults can help in guiding allocation of organs to recipients who
e most likely to benefit in the long term. However, nationally
reed-on allocation priorities of the OPTN use waiting time
d a liver failure severity metric (Model for End-Stage Liver
isease score) as the dominant criteria for achieving fairness
kidney and liver allocation, respectively; allocation
hemes that seek to maximize net societal benefit from
nated allografts have not been adopted. Although prognos-
c information from noninvasive cardiac testing of asymp-
matic patients may be useful for adjusting center perfor-
ance metrics such as post-transplantation mortality for the
ase mix” of each center’s recipients, this approach would
cur substantial expense compared with the use of informa-
on available from the history and physical examination.
Some patients have been shown to undergo renal trans-
antation safely despite clinical markers of high cardiovas-
lar risk. Jeloka et al. (35) retrospectively classified 429
nal transplant recipients as high cardiovascular risk (n61)
d low cardiovascular risk (n368). The high-risk group
cluded patients with a history of angina, MI, or significant
AD found on cardiac catheterization. Outcomes of interest
ere post-transplantation cardiac events (MI, angina, new
rhythmias, heart failure, and/or sudden cardiac death) and
erall survival. The distribution of events among the high-
sk and low-risk groups was 31.3% versus 6.5%, respectively
0.001). Five-year survival in the high-risk group was
.8% compared with 93.1% in the low-risk group
0.004). Among the subgroup who underwent coronary
vascularization before transplantation (n28; 25% PCI,
% CABG), 43% subsequently experienced a cardiac event.
he authors contended that in selected high-risk patients,
erall 5-year survival after renal transplantation was actually
ite good, superior to the expected 5-year survival with
ntinued dialysis.
With regard to the pathophysiology of perioperative car-
ac events, both demand-mediated ischemia and plaque
pture contribute to perioperative cardiac events. The stress
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July 31, 2012:434–80 Cardiac Disease Evaluation and Management Among Transplantation Candidatessponse from surgery can lead to increases in heart rate and
ood pressure, which can precipitate episodes of “demand
chemia” in myocardial areas distal to a coronary artery
enosis (36). Long periods of myocardial ischemia (either
olonged individual episodes or cumulative duration of
orter episodes) have been associated with myocardial
crosis and perioperative MI and death (37–39). A major
echanism of MI in the nonoperative setting is plaque
pture of a noncritical coronary stenosis with subsequent
ronary thrombosis (40). The perioperative period is char-
terized by tachycardia, increased sheer stress, and a hyper-
agulable state; thus, plaque rupture and thrombosis may
so occur in this context (41). Ellis et al. (42) demonstrated
at one third of all patients with perioperative MI sustained
mage in areas distal to noncritical stenoses. Dawood et al.
3) demonstrated that fatal perioperative MI occurs predom-
antly in patients with multivessel CAD, especially left main
d 3-vessel disease; however, the severity of preexisting
derlying stenosis did not predict the resulting infarct
rritory. Because the nidus for the thrombosis is often a
ncritical stenosis, preoperative cardiac evaluation before
rgery may fail to identify patients at risk for plaque rupture,
though control of heart rate may decrease the propensity of
aque rupture regardless of stenosis severity. The areas distal
a noncritical stenosis typically will not have much collat-
al coronary flow; therefore, any acute thrombosis may lead
extensive downstream myocardial necrosis. Methods of
eoperative cardiovascular testing do not identify patients
ith mild to moderate but “vulnerable” coronary plaques.
etermining Whether the
ransplantation Candidate
as an Active Cardiac Condition
primary goal of the preoperative evaluation is to establish
hether an active cardiac condition is present. Clinical
sessment should occur during the initial evaluation and
ain immediately before anticipated transplantation to de-
rmine whether there has been an interval change in cardio-
scular conditions. “Active” conditions include unstable
ronary syndromes (e.g., unstable angina, severe angina, or
cent MI), decompensated heart failure, significant arrhyth-
ias, and severe valvular disease. The presence of one or
ore of these conditions is associated with high rates of
rioperative cardiovascular morbidity and mortality and
ay require delay or cancellation of surgery.
ecommendation
A thorough history and physical examination are
recommended to identify active cardiac conditions
before solid-organ transplantation (Class I; Level of
Evidence C).
A number of chronic cardiac conditions also merit consid-
ation and at times may require further assessment before
rgery. These include chronic limiting angina, an MI that is
30 days old but without symptoms of unstable angina, a
ior history of CABG or PCI, decompensated heart failure, onoderate valvular disease or prior valve surgery, or stable
rhythmias.
erioperative Risk Assessment Based
n Symptoms and Exercise Tolerance
he presentation of acute and chronic ischemia may differ in
tients with ESRD compared with people without kidney
ilure. Among patients hospitalized with acute MI and
corded in the third National Registry of Myocardial Infarc-
on, chest pain at presentation was reported less commonly
ong patients on dialysis compared with non–dialysis-
pendent patients (44.4% versus 68.3%) (44). In the
mmunity-based study of patients hospitalized with acute
I in Worcester, MA, patients with kidney disease were less
kely to report chest pain (adjusted odds ratio [OR], 0.57)
d more likely to report shortness of breath (OR, 1.35)
mpared with patients without kidney disease in the setting
acute MI (45). In a preliminary report of symptoms during
CI among 111 patients who had undergone 256 interven-
ons, silent myocardial ischemia, defined as the absence of
est pain in response to balloon dilatation of the affected
ssel, was present in 59.1% of the sample with CKD
efined as estimated glomerular filtration rate [eGFR]
60 mL/min/1.3 m2) compared with 29.1% without CKD
6). However, the value of screening to identify asymp-
matic patients likely to benefit from revascularization is
clear. In the randomized DIAD (Detection of Ischemia
Asymptomatic Diabetics) trial of MPS versus medical
llow-up among asymptomatic patients with type 2 dia-
tes mellitus, use of MPS screening had no discernable
fect on subsequent cardiac events over 5 years of
llow-up (47).
Exercise tolerance is 1 correlate of perioperative risk and is
cornerstone of the testing algorithm reported in the “ACC/
HA 2007 Guidelines on Perioperative Cardiovascular Eval-
tion and Care for Noncardiac Surgery” (7). In 1 study of
tpatients referred for evaluation before major noncardiac
ocedures, patients were asked to estimate the number of
ocks they could walk and flights of stairs they could climb
ithout experiencing cardiac symptoms (48). Patients who
uld not walk 4 blocks and climb 2 flights of stairs were
nsidered to have poor exercise tolerance and were found to
ve twice as many perioperative cardiovascular complica-
ons as those with better functional status. The likelihood
serious complications was inversely related to the
mber of blocks that could be walked or flights of stairs
at could be climbed. Further work is needed to determine
e ability of functional status to discriminate the likeli-
od of prognostically significant CAD among transplan-
tion candidates.
perfect Correlations of Angiographic CAD
nd Clinical Outcomes in ESRD
ngiographic studies from the 1970s to early 1990s reported
tection of coronary stenoses in high proportions of patients
long-term dialysis (49–52). More recently, angiographi-
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Cardiac Disease Evaluation and Management Among Transplantation Candidates July 31, 2012:434–80lly significant CAD was found in 53% of a sample of 30
tients with incident ESRD without known cardiac history
ho consented to screening angiography, including 10 of the
participants (83%) with diabetes mellitus, although nota-
y angiographic significance was liberally defined as lesions
50% (54). Recent reports of angiography in patients under-
ing transplantation evaluation have documented CAD in
% to 90% of participants, with a higher prevalence in
mples defined as high risk by clinical criteria and with use
more liberal angiographic definitions of CAD (26,59–61)
able 4).
Studies describing associations of angiographic coronary
enoses with subsequent clinical events in patients with
SRD, including those undergoing transplantation evalua-
ons, have reported variable results (Table 4). In 1
ospective study of 106 renal transplantation candidates
inically classified as moderate (age 50 years) or high
iabetes mellitus, extracardiac vascular disease, or known
AD) coronary risk, participants underwent MPS, DSE,
d coronary angiography (56). Clinical risk stratification
d coronary angiography predicted MACEs after a me-
an follow-up of 46 months, but results of MPS and DSE
d not. Several observational studies reported an in-
eased unadjusted risk of all-cause mortality and MACEs
patients with angiographic CAD (55,58), whereas other
vestigations identified excess risk in only certain patient
bgroups such as those with proximal CAD (57) or with
ndiabetic renal failure (59). Several recent studies have
und no associations of CAD with subsequent patient
rvival (28,60,61).
ccuracy of Noninvasive Testing for CAD
Kidney Transplantation Candidates
oninvasive testing for CAD has imperfect sensitivity and
ecificity in patients with renal failure. Table 5 summarizes
e association between cardiac stress testing results and
clusive coronary artery lesions on angiography in cohorts
ith CKD stage 5 (GFR 15 mL/min/1.73 m2 or dialysis
pendent). Studies were included if stress was induced by
ercise or pharmacological means and if CAD was detected
electrocardiography, echocardiography, or radionuclide
aging. Studies were excluded if not all subjects selected for
ress testing underwent angiography. Across this collection
studies, DSE and MPS had sensitivities varying from 0.44
0.89 and 0.29 to 0.92 and specificities ranging from 0.71 to
94 and 0.67 to 0.89, respectively, for identifying 1 or more
ronary stenoses 70% (55,56,63–69). The type of stress
aging may have different operational characteristics in ESRD
tients. In 1 study of coronary flow reserve in 64 patients with
rmal epicardial arteries, 57% (12 of 21) of those with diabetic
phropathy had high resting coronary basal flow with no
cremental response to adenosine compared with 18% of
tients (2 of 11) with diabetes mellitus without renal failure and
(3 of 32) of patients without diabetes mellitus (70), suggest-
g impaired vasodilator reserve in patients with ESRD with
abetes mellitus. Overall, the accuracy of inotropic stress
hocardiography for the purpose of screening to identify wgh-risk anatomy may be somewhat superior to that of vasodi-
tor stress nuclear perfusion imaging.
Nonetheless, abnormal MPS and DSE test results have
en associated with prognostic value for cardiac events and
ortality in the ESRD population (27,55,67,69,71–76). In a
eta-analysis of 12 studies involving either thallium-201
intigraphy or DSE, patients with ESRD with inducible
chemia had 6 times the risk of MI and 4 times the risk of
rdiac death as patients without inducible defects (77).
oreover, patients with fixed defects had nearly 5 times the
sk of cardiac death. Among 485 patients with advanced
dney disease, the percentage of ischemic segments by DSE
as an independent predictor of mortality and offered prog-
stic information beyond clinical characteristics alone (78).
a study of 126 patients with ESRD who underwent
chnetium-99m MPS as part of their pretransplantation assess-
ent, the presence of a reversible defect was associated with 3
es the risk of post-transplantation cardiac events and nearly
ice the risk of death compared with normal test results (79).
onsiderations for Kidney
ransplantation Candidates
ith Diabetes Mellitus
ne of the main discrepancies between guideline recommen-
tions from the ACC/AHA and the renal/transplant organi-
tions (NKF/KDOQI, AST) is that the latter advise routine
rdiac screening with noninvasive cardiac imaging in pa-
ents with diabetes mellitus on the basis of concerns for
ilent” (asymptomatic) ischemia (12,14). NKF/KDOQI also
vocates repeat screening annually while a patient with diabe-
s mellitus is on the waitlist (12). In consideration of cardiac
aluation practices in patients with diabetes mellitus with
SRD, it is useful to review strategies that have been applied to
duce cardiac risk in the broader diabetic population.
In 1998, the American Diabetes Association recommended
utine stress testing in asymptomatic patients with diabetes
ellitus with 2 traditional cardiovascular risk factors in
dition to diabetes mellitus (80). More recent data call these
commendations into question. In the prospective DIAD
udy (47), 1,123 asymptomatic patients with type 2 diabetes
ellitus 50 to 75 years of age were randomized to adenosine
chnetium-99m sestamibi-MPS or medical follow-up. The
imary endpoint was cardiac death or nonfatal MI over 5
ars. Coronary revascularization within 120 days of random-
ation occurred in 1.6% of the screened group and 0.4% of
e nonscreened group. There was no difference in the
equency of the primary endpoint according to screening
signment: 7 nonfatal MIs and 8 cardiac deaths (2.7%)
curred in the screened group compared with 10 nonfatal
Is and 7 cardiac deaths (3.0%) in nonscreened group
azard ratio [HR], 0.88; 95% confidence interval [CI], 0.44
1.88; p0.73). There was also no difference in the
cidence of unstable angina, chronic heart failure, or stroke
tween the groups. Of those screened, 409 patients had
rmal MPS; 33 patients with large or moderate defects had
annual event rate of 2.4% compared with the 50 patientsith small perfusion defects and an annual event rate of 0.4%.
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July 31, 2012:434–80 Cardiac Disease Evaluation and Management Among Transplantation Candidatesble 4. Recent Descriptions of the Outcome Implications of Angiographic CAD in Patients With ESRD,
cluding Transplantation Candidates
Authors, Year Participants and Design
Selection Criteria
for Angiography
Angiographic Definition
of CAD Estimated CAD Prevalence
Associations of CAD With
Clinical Events
Lima et al. (56),
03
106 patients presenting for
KT evaluation at 1 center
and deemed at moderate
or high coronary risk
(1998–2002)
Prospective
Moderate risk: age
50 y
High risk: history of
diabetes, MI,
angina, stroke,
LV dysfunction,
peripheral vascular
disease
Willing to consent
70% stenosis in
1 epicardial arteries
by visual estimation
Evaluation by
2 observers
CAD present in 42%
(44 of 106)
1-, 2-, and 3-vessel CAD in
19%, 16%, and 7%,
respectively
MACEs, defined as sudden
death, MI, arrhythmia,
heart failure, unstable
angina, or
revascularization
Unadjusted probability of
reaching endpoint at 1, 2,
and 4 y was higher with
angiographic CAD
(p0.001): 13%, 39%,
and 46% versus 2%, 6%,
and 6% in the absence of
CAD
arma et al. (55),
05
125 consecutive patients
referred for KT evaluation
Age 18 y
Free of severe
aortic stenosis or
unstable angina
Willing to consent
Severity by degree of
luminal narrowing:
mild, 50%;
moderate, 50%–70%;
severe, 70%
Evaluation by
2 observers
CAD present in 64%
(80 of 125)
Severe, moderate, and mild
CAD in 29%, 14%, and 21%
Unadjusted survival at
2 years was significantly
lower among those with
versus without CAD (85%
versus 100%; p0.005)
arytan et al. (57),
07
67 prevalent hemodialysis
patients (1998); subset of
a larger study (N224)
Prospective
Free of ischemic
symptoms at
enrollment
Free of coronary
events within 4 wk
No coronary
angiography within
previous 2 y
Willing to consent
50% narrowing
compared with
adjacent normal
segment by digital
calipers
Evaluation by
2 observers
CAD in 42% (28 of 67),
including involvement of
proximal third of an
epicardial vessel in 28.5%
Of 28 subjects with CAD,
75% had multivessel and
68% had proximal lesions
Over a median 2.7 y of
observation, the presence
of any CAD was
associated with increased
risk of death
Only proximal CAD was
associated with mortality
in adjusted analyses (aHR,
3.14; 95% CI, 1.34 to 7.33)
wdak et al. (58),
07
301 patients referred for
KT evaluation and deemed
at high coronary risk
Inclusion criteria:
history of diabetes
mellitus, prior
cardiovascular
disease (MI,
unstable angina,
stroke, LV
dysfunction, or
extracardiac
atherosclerosis), or
age 50 y
Willing to consent
70% luminal
reduction in 1
epicardial arteries
Evaluation by
2 observers
Significant CAD in 45%
(136 of 301)
MACEs, defined as MI,
unstable angina, sudden
death, unplanned coronary
or peripheral arterial
revascularization, stroke,
or heart failure
Over a median 1.8-y
observation, crude
incidence of MACEs was
higher in those with CAD
(45% versus 18%;
p0.001)
wdak et al. (59),
07
288 patients referred for
KT evaluation; portion of
the cohort in the previous
study (58)
High clinical risk,
as defined
previously (58)
70% luminal
reduction in 1
epicardial arteries
Evaluation by
2 observers
Significant CAD in 43%
(124 of 288)
MACE as defined
previously (58)
CAD was associated with
significantly higher crude
relative risk of MACEs
among nondiabetic
patients (HR, 4.3; 95% CI,
2.4 to 7.9; p0.001)
No significant association
of CAD with MACEs in
diabetic patients(Continued)
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Cardiac Disease Evaluation and Management Among Transplantation Candidates July 31, 2012:434–80In DIAD and another prospective study of asymptomatic
tients with diabetes mellitus, the proportion of patients with
abnormal MPS was identical in those who did and did not
eet American Diabetes Association criteria for recom-
ended screening (47,81). In 1 study, the only difference was
lated to the extent of CAD, with more severe CAD
entified in the group recommended for screening (81).
Is screening necessary in asymptomatic patients with
abetes mellitus without known CAD to justify more aggres-
ve medical therapy or to identify patients who should be
nsidered for coronary revascularization? Regarding the
tion of optimal medical therapy, patients with diabetes
ellitus without prior MI appear to have cardiac event rates
mparable to those of patients without diabetes mellitus with
history of prior MI (82). Thus, results of screening will not
nerally mitigate the need for optimal medical management.
sing the specific example of statin therapy in this subgroup,
iamond and colleagues (83) argue that the strategy of “test
one and treat everyone” is more cost-effective than
creen everyone with a test and treat only those with an
normal test,” thereby obviating the need for routine
ble 4. Continued
Authors, Year Participants and Design
Selection Criteria
for Angiography
An
ge et al. (60),
07
260 patients studied by
angiography from a cohort
of 3,698 referred for KT
evaluation at 1 center
(2001–2004)
Retrospective
Positive stress
MPS, known CAD,
or discretion of
cardiologist

dia
an
co
ma
ma
eq
CA
Re
cli
tel et al. (28),
08
99 patients studied by
angiography from a cohort
of 300 referred for KT
evaluation at 1 center
(2002–2005)
Retrospective
Angiography
suggested if age
50 y, ESRD
caused by diabetes
mellitus,
symptomatic IHD or
positive noninvasive
testing
Final selection
based on clinical
judgment and
patient preference
Ob
No
ste

ckson et al. (61),
08
132 patients studied by
angiography from a cohort
of 644 referred for KT
evaluation at 1 center
(2004–2006)
Retrospective
Angiography
performed if DSE
was positive,
cardiologist
recommended
Se
de
sin
ar
mo
se
aHR indicates adjusted hazards ratio; CAD, coronary artery disease; CI, con
sease; HR, hazards ratio; IHD, ischemic heart disease; KT, kidney transplantati
farction; and MPS, myocardial perfusion scintigraphy.
Reproduced from Lentine et al. (62) with permission from Elsevier. Copyrighreening. noThe value of screening to identify asymptomatic patients
kely to benefit from coronary revascularization procedures
even less clear. As previously mentioned, certain small
bgroups with high-risk coronary artery anatomy probably
hieve survival benefit from CABG surgery (31,31a). In
tients with stable CAD and lesser extents of coronary
sease, coronary revascularization has not been demon-
rated to provide benefit over optimal medical therapy
hen studied in a randomized fashion before elective
scular surgery (9 –11). In the DIAD study (47), coronary
vascularization was infrequent (2% within 120 days of
ndomization in both arms), and the treatment after MPS
reening did not significantly reduce the risk of cardiac
ents. The authors concluded that MPS screening of
ymptomatic patients with type 2 diabetes mellitus to
entify revascularization candidates did not reduce car-
ac event rates. This study did not address patients with
nal failure.
In summary, on the basis of available data, routine nonin-
sive screening of patients with diabetes mellitus either for
ritransplantation cardiac evaluation or for long-term care is
hic Definition
CAD Estimated CAD Prevalence
Associations of CAD With
Clinical Events
en
arrowing in
ajor
rteries or
ches; left
idered
to 2-vessel
tained from
orts
CAD in 62% (162 of 260)
1-, 2-, and 3-vessel CAD in
16%, 13%, and 33%,
respectively, of the sample
submitted to angiography
36% (94 of 260) of the
angiography group
underwent revascularization
Presence and severity of
CAD were not associated
with crude survival among
those who underwent
angiography; 2-y survival:
80%, 88%, 86%, and
78% for 0-, 1-, 2-, and
3-vessel disease (p0.6)
e, 75%
ctive,
resent but
CAD in 57.6% (57 of 99)
Obstructive CAD in 34.3%
(34 of 99), including 1-, 2-,
3-vessel CAD in 13%, 15%,
and 6%, respectively, of the
angiography sample
Nonobstructive CAD in 23%
17% (17 of 99) of the
angiography group
underwent revascularization
No difference in crude 4-y
survival in patients found
to have CAD and
revascularized compared
with those who underwent
angiography without
revascularization or those
not studied by
angiography (p0.7)
y highest
stenosis of
or epicardial
ild, 50%;
50%–70%;
70%
CAD present in 90%
(119 of 132) of those
studied by angiography
Severe, moderate, and mild
in 56%, 10%, and 25% of
the angiography sample
40 of 644 of the full cohort
underwent revascularization
before listing
Over a median 6-mo
observation, severity of
CAD by angiography was
not significantly associated
with mortality in the full
cohort (p0.2)
interval; DSE, dobutamine stress echocardiography; ESRD, end-stage renal
eft ventricular; MACEs, major adverse cardiovascular events; MI, myocardial
American Kidney Foundation.giograp
of
50% lum
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July 31, 2012:434–80 Cardiac Disease Evaluation and Management Among Transplantation Candidatesummary and Recommendations
egarding Noninvasive Stress Testing
Kidney Transplantation Candidates
ithout Active Cardiac Conditions
oninvasive cardiac stress testing by DSE or MPS has some
ognostic value for cardiac events and mortality but imper-
ct sensitivity and specificity for detecting angiographically
fined CAD in patients with ESRD. Associations of CAD by
giography with subsequent survival in ESRD are also
consistent, likely because plaque instability is more impor-
nt for risk of MACEs than angiographic stenosis and many
aque ruptures producing MI are not localized to sites of
giographic stenosis (40). Furthermore, coronary revascu-
rization in asymptomatic patients without end-stage organ
ilure has failed to show benefit except in a small subset of
gh-risk anatomic lesions. Evidence does not support suffi-
ent prevalence of such high-risk anatomy among asymp-
matic patients to warrant routine coronary angiography in
l potential transplantation candidates. In the randomized
IAD trial of MPS versus medical follow-up among asymp-
matic patients with type 2 diabetes mellitus for the purpose
identifying revascularization candidates who may not
herwise come to clinical attention, coronary revasculariza-
on was infrequent (47).
The Writing Committee acknowledges that there are no
finitive data at this time for or against screening for myocar-
al ischemia among kidney transplantation candidates who are
ble 5. Accuracy of Noninvasive Testing for Detection of Coron
Authors, Year Study Population n Stress Te
rwick et al. (63) 100% KT candidates
Mean age 4911 y
45 Dipyridamolethall
56% had diabetic nephropathy
udreau et al. (64) 100% KT candidates
100% had diabetes mellitus
80 Dipyridamole
ndenberg et al. (65) 100% KT candidates
Mean age 379 y
41 Dipyridamole/aden
100% had diabetes mellitus
35 Exercise tha
han et al. (66) HD for 6 mo, no overt CAD
Mean age 5411 y
60 Dipyridamole/exerc
SPECT
23% had diabetes mellitus
rzog et al. (67) 100% KT candidates 50 DSE
Mean age 5111 y
78% had diabetic nephropathy
orthley et al. (68) 100% KT candidates 40 Exercise/pacingt
nuclide ima
Mean age 509 y
78% had diabetes mellitus
Lima et al. (56) 100% KT candidates 89 DSE
102 Dipyridamole
arma et al. (55) 100% KT candidates 125 DSE
Mean age 5212 y
39% had diabetes mellitus
55% were on dialysis
rreira et al. (69) 100% KT candidates
Mean age 529 y
27% had diabetic nephropathy
148 Dobutamine/a
echocardiog
CAD indicates coronary artery disease; CAS, visual coronary angiographic s
nsplantation; NPV, negative predictive value; PPV, positive predictive value; QC
mputed tomography.ee of active cardiac conditions. However, until more data are Tailable, it may be useful to use aggregate CAD risk factors to
rget screening of patients with the highest pretest likelihood of
ognostically significant CAD.
The “ACC/AHA 2007 Guidelines on Perioperative Cardio-
scular Evaluation and Care for Noncardiac Surgery” high-
ght 4 “active cardiac conditions” that indicate major clinical
sk (7). These include unstable coronary syndromes (unsta-
e angina or recent MI), decompensated heart failure, sig-
ficant arrhythmia, and severe valvular heart disease. If none
the active cardiac conditions is present, the patient is then
sk stratified on the basis of functional capacity. If the
nctional status is estimated as 4 METS in a patient
ithout an active cardiac condition, then that patient is
emed low risk and no further testing is advocated. If
nctional capacity is 4 METS, it is difficult to know
hether the low level of exertion is preventing manifestation
an active cardiac condition or whether cardiac conditions
e truly absent. Therefore, such patients with low functional
pacity are considered to be of indeterminate cardiac risk.
he ACC/AHA approach then further risk stratifies asymp-
matic patients with low functional capacity according to the
esence or absence of risk markers: ischemic heart disease,
mpensated or prior heart failure, diabetes mellitus, renal
sufficiency, and cerebrovascular disease. Because the pres-
ce of any of these risk markers is associated with increased
kelihood of CAD among patients with poor functional
atus, the diagnostic yield of noninvasive stress testing
eoretically improves as one acquires more risk factors.
tery Stenosis in End-Stage Renal Disease Patients
Endpoint
Endpoint
Prevalence Sensitivity Specificity PPV NPV
T CAS 50%
CAS 70%
0.42 0.37 0.73 0.50 0.61
0.31 0.29 0.68 0.29 0.68
QCAS 70% 0.53 0.86 0.79 0.82 0.83
um CAS 50%
CAS 75%
0.46 0.53 0.73 0.63 0.36
0.39 0.63 0.76 0.63 0.24
CAS 50% 0.46 0.44 0.63 0.50 0.57
CAS 75% 0.40 0.50 0.67 0.50 0.67
um CAS 70% 0.22 0.92 0.89 0.71 0.98
QCAS 50% 0.54 0.52 0.74 0.70 0.57
QCAS 70% 0.24 0.75 0.71 0.45 0.90
CAS 75% 0.32 0.75 0.76 0.60 0.87
n CAS 70% 0.38 0.87 0.88 0.81 0.92
CAS 70% 0.38 0.44 0.87 0.53 0.60
CAS 70% 0.23 0.35 0.76 0.72 0.68
CAS 70% 0.29 0.89 0.94 0.86 0.95
CAS 50%
CAS 70%
0.530.71 0.870.85
DSE, dobutamine stress echocardiography; HD, hemodialysis; KT, kidney
ntitative coronary angiographic stenosis; and SPECT, single photon emissionary Ar
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Cardiac Disease Evaluation and Management Among Transplantation Candidates July 31, 2012:434–80t to consider “pretest probability” in the strategy for
ninvasive stress testing, the ACC/AHA guideline recom-
ends preoperative stress testing on the basis of the presence
a certain number of risk factors depending on the surgery-
ecific risk. However, this scheme was designed for a wide
e range of patients (including the elderly) with a wide range
chronic medical conditions.
The question arises as to whether the overall ACC/AHA
heme could be customized to the transplantation popula-
on. Of note, the transplantation population is on average
unger than the general population. Therefore, the func-
onal status of 4 METS may not be as discriminating. One
udy of 204 consecutive transplantation candidates with no
tive cardiac conditions reported that 80% had a functional
atus 4 METS and that functional status was not a useful
scriminator for the presence of CAD (24). Importantly,
tients scheduled for renal transplantation have at least 1
inical risk marker (azotemia), and diabetes mellitus is a
mmon additional risk marker in this population, rendering
e provided list less useful for risk stratification. Further-
ore, the ACC/AHA guideline is also designed for short-
rm risk assessment, whereas both short-term management
d long-term management of CAD are important consider-
ions among transplantation candidates.
Kidney transplantation is typically considered an “intermediate-
sk” surgery. However, few studies have evaluated the utility of
inical risk markers for the risk of MACEs during the
ansplantation hospitalization or within 30 days of transplan-
tion surgery (the usual approach in nontransplantation,
ncardiac surgery). This distinction is important because
rioperative risk stratification has traditionally focused on
entifying patients with undiagnosed or unstable CAD as a
ay to reduce the risk of MACEs after surgery. In a
trospective study of 2,187 transplant recipients, Aalten et al.
4) reported independent associations of recipient age,
abetic nephropathy, claudication, and prior cardiac events
ith an increased risk of cardiac events (defined as MI,
ronary revascularization, stroke, or cardiac death) within
e first 3 months after kidney transplantation.
With respect to longer-term prognostication, the Framing-
m Heart Study (FHS) score, a composite index designed to
edict coronary heart disease in the general population based
traditional risk markers of age, sex, cholesterol levels,
pertension, and diabetes mellitus status, has modest to
oderate ability to predict long-term coronary events among
dney transplantation patients. Although individual Fra-
ingham risk factors are significantly associated with coro-
ry risk among kidney transplant recipients, effect sizes are
tered so that FHS risk predictions are generally lower than
served risk in this population. Features of this miscalcula-
on include largest errors among patients at highest risk,
iven in part by underestimation of diabetes mellitus–related
sk. For example, in a retrospective study of 1,124 kidney
ansplant recipients with stable graft function at the first
ansplantation anniversary, the FHS score underestimated
e risk of coronary events as a result of increased observed
sk conferred by diabetes mellitus (HR in men, 2.8 versus 1.5
FHS; HR in women, 5.4 versus 1.8 in FHS) and, to a lesser
tent, age and smoking in the transplanted sample (85). In thother historical cohort study of transplant recipients with
nctional allografts at 1 year after transplantation, the FHS
edicted 59% of observed coronary events (86). A prospec-
ve cohort evaluation of 540 prevalent transplant recipients
rolled at average of 6.6 years after transplantation and
llowed up for an average of 4.7 years found that the ratio of
served to predicted cardiac events based on the FHS was
64 for the cohort overall (87). Observed cardiac events rates
ceeded FHS predictions in patients with pretransplantation
abetes mellitus and those with prior cardiac disease, being
74 times the predicted risk in patients 45 to 60 years of age
ith prior cardiac disease or diabetes mellitus (87). However,
served risk did not exceed predictions in older patients
nsidered without regard to comorbidity or in younger
tients free of prior diabetes mellitus or cardiac history.
One alternative to use of the ACC/AHA-defined CAD risk
ctors for the general population is to consider risk factors
ore specific to the transplantation population, as suggested
the 2007 Lisbon Conference report (13). Compared with
e ACC/AHA approach, this strategy appeared to improve
nsitivity and specificity for the identification of CAD
ensitivity, 94% versus 77%; specificity, 33% versus 24%)
d to reduce the overall frequency of testing in 1 single
nter (24). The risk factors for CAD deemed relevant to
ansplantation candidates in the Lisbon Conference report
clude diabetes mellitus, prior cardiovascular disease, 1
ar on dialysis, left ventricular hypertrophy, age 60 years,
oking, hypertension, and dyslipidemia.
ecommendation
Noninvasive stress testing may be considered in kidney
transplantation candidates with no active cardiac con-
ditions based on the presence of multiple CAD risk
factors regardless of functional status. Relevant risk
factors among transplantation candidates include dia-
betes mellitus, prior cardiovascular disease, more than
1 year on dialysis, left ventricular hypertrophy, age
greater than 60 years, smoking, hypertension, and
dyslipidemia. The specific number of risk factors that
should be used to prompt testing remains to be deter-
mined, but the committee considers 3 or more as
reasonable (Class IIb; Level of Evidence C).
ardiac Surveillance After Listing
r Transplantation
st as there is uncertainty about which patients to screen, the
timal frequency for repeat noninvasive stress testing for
tients awaiting renal transplantation is not known. The
KF/KDOQI guidelines recommended repeat stress testing
ith imaging once a year among subgroups on the transplant
st including patients with diabetes mellitus regardless of
mptoms (12). These guidelines mirror recommendations
om the AST’s 2002 conference on management of the
ansplant waitlist (88). However, the cardiac event rate
ardiac death or nonfatal MI) was only 0.6% over 2 to 3
ars in 7,376 patients with a normal MPS, suggesting that
e “warranty” on a normal stress perfusion scintigram is at
le
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July 31, 2012:434–80 Cardiac Disease Evaluation and Management Among Transplantation Candidatesast 2 years in a general population (90); however, only 10%
participants in this study were diabetic. There are few data
fining the long-term prognosis conferred by a normal study
individuals with diabetes mellitus. A large cohort study
und low and similar cardiac event rates between individuals
ith and without diabetes mellitus up to 2 years after normal
ress MPS beyond that, the cohort with diabetes mellitus
perienced a greater event rate (90). Prognosis after a normal
PS also varies with renal function. In an observational cohort
udy of the Veterans Affairs database with an average of 2 years of
llow-up that considered outcomes according to CKD status
efined as eGFR 60 mL/min/1.73 m2), the annualized rate of
rdiac death after a normal MPS (defined as no scar or ischemia)
se in a graded manner with declining renal function: eGFR
90 mL/min/1.73 m2 to 0.4%; eGFR 60 to 89 mL/min/1.73 m2
0.9%; eGFR 30 to 59 mL/min/1.73 m2 to 2.2%; and eGFR
30 mL/min/1.73 m2 to 4.7% (91).
In a cohort study from Brisbane, Australia, including 107
tients with CKD with baseline and repeat DSE tests after a
ean follow-up of 1.8 years, 19% of the 73 patients with
rmal DSE results at baseline developed inducible ischemia
new scar on repeat testing (92). Despite this potential for
nversion of normal noninvasive tests to abnormal at a rate
10%/y, an argument that “periodic cardiac surveillance
sting after waitlist may be unnecessary” is supported by a
ospective, observational study of patients on the kidney
ansplant waitlist in British Columbia in 1998 to 2001 (93).
mong kidney transplantation candidates with normal cardiac
ress testing at listing, the reference cardiac surveillance guide-
e included recommendation for annual testing in those with
abetes mellitus, testing every 2 years in those with ischemic
art disease or peripheral vascular disease, and testing every 3
ars in others. Surveillance based on ongoing clinical assess-
ent resulted in fewer investigations than suggested by guide-
es over a mean follow-up period of 3.7 years. There was no
fference in total cardiovascular event rates after listing among
bsets who received the recommended frequency of investiga-
ns compared with those in whom testing was guided by
mptoms.
ecommendation
The usefulness of periodically screening asymptomatic
kidney transplantation candidates for myocardial isch-
emia while on the transplant waiting list to reduce the risk
of MACEs is uncertain (Class IIb; Level of Evidence C).
upplemental Testing
vidence for Resting Echocardiography in
idney Transplantation Candidates
he NKF/KDOQI “Clinical Practice Guidelines for Cardio-
scular Disease in Dialysis Patients” recommend that a
sting echocardiogram “should be performed in all patients
the initiation of dialysis, once the patient has achieved dry
eight (ideally within 1–3 months of dialysis initiation)”
2). This is considered by the working group as a Level of
vidence A recommendation, which implies the strongest Lcommendation. A number of studies have demonstrated the
edictive value of resting echocardiographic findings for
verse events in dialysis patients.
Foley et al. (94) collected clinical and echocardiographic
ta at the time of hemodialysis initiation in 433 patients and
llowed the cohort prospectively for survival over 41
onths. Cardiovascular disease was common at baseline, and
least 1 cardiovascular condition was noted in 43%. Base-
ne echocardiographic abnormalities included left ventricular
pertrophy in 74%, dilated left ventricle in 36%, and
stolic dysfunction in 15%. Predictors of mortality included
vanced age, chronic heart failure, diabetes mellitus, and
hocardiographic parameters of left ventricular enlargement
systolic dysfunction, whereas a history of CAD alone was
t associated with survival.
Sharma et al. (55) examined 125 potential renal transplan-
tion candidates by resting electrocardiogram (ECG), exer-
se ECG, DSE, and coronary angiography (Table 4). Corre-
tes of coronary stenosis of70% included abnormal resting
CG, increased left ventricular size, decreased LVEF, resting
all motion abnormalities, and ischemia identified by echo-
rdiographic imaging, whereas cardiac symptoms and exer-
se ECG findings were not significantly associated with
giographic CAD.
Among 485 patients with advanced kidney disease, inde-
ndent predictors of mortality over 2.31.8 years included
sting LVEF and ischemia on stress echocardiogram; once
ain, stress ECG findings were not associated with mortality
8). Three-year survival was superior in patients with a
rmal stress echocardiogram (70%) compared with patients
ith fixed defects or ischemia in 25% left ventricular
gments (57%), and survival was poorest (48%) in patients
ith ischemia in 25% of left ventricular segments.
Two reports from 1 large center using stress MPS in
tential candidates meeting AST criteria for pretransplanta-
on CAD evaluation found left ventricular systolic dysfunc-
on, defined as LVEF 40% to 45%, in 16% to 18% of
tients (95,96). The majority (61%–63%) of these patients
d not have evidence of ischemia by perfusion imaging.
edian survival in patients with LVEF40% was 49 months
mpared with 72 months in patients with higher LVEF; after
justment for ischemia and other risk factors, the relative
sk of mortality increased by 2.5% for each percent decline
LVEF (96).
In one of the largest series reported to date, Yamada et al.
7) examined 1,254 consecutive incident hemodialysis pa-
ents in Japan with echocardiography within 1 month after
alysis initiation. LVEF levels 60%, 50% to 60%, 40% to
%, 30% to 40%, and 30% were observed in 67.1%,
.7%, 8.5%, 3.3%, and 1.4% of patients, respectively. On
aplan-Meier analysis, 7-year event-free rates from cardio-
scular death were 84.2%, 83.7%, 73.6%, 59.4%, and
.9%, respectively, according to each 10% decrease in
VEF. In multivariate models, LVEF bore graded associ-
ions with the risk of subsequent cardiovascular and
l-cause mortality, with more than 9 times the relative risk
cardiovascular death (adjusted HR, 9.42; 95% CI, 3.82
23.3) among those with LVEF 30% compared withVEF 60%.
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Cardiac Disease Evaluation and Management Among Transplantation Candidates July 31, 2012:434–80In summary, collective evidence supports the concept that
hocardiographic findings at rest and after stress provide
ognostic information for long-term mortality in patients
ith CKD. The strong relationship between LVEF and
tcomes supports the need for vigorous efforts to identify
y reversible cause of poor LVEF and, where possible, and
correct these causes before proceeding to transplantation.
arvedilol treatment reduced the risk of cardiovascular mor-
lity (relative risk [RR], 0.32), all-cause death (RR, 0.51),
d hospitalizations (RR, 0.44) compared with placebo in a
all randomized trial of 114 dialysis patients with dilated
rdiomyopathy (98), supporting the use of echocardiography
r guiding therapy and for prognostication. Notably, im-
ovement in abnormal LVEF and heart failure symptoms in
me patients with ESRD, probably those with uremic
rdiomyopathy, has been reported after transplantation
6,99–101).
ecommendation
It is reasonable to perform preoperative assessment of
left ventricular function by echocardiography in po-
tential kidney transplantation candidates (Class IIa;
Level of Evidence B). There is no evidence for or
against surveillance by repeated left ventricular func-
tion tests after listing for kidney transplantation.
Other findings on a baseline echocardiogram beyond wall
otion assessment may have prognostic significance for the
nal transplantation candidate.
alve Disease
verall, the management of valvular heart disease in renal
ansplantation candidates is similar to that in the general
pulation, and the reader is directed to the “2008 Focused
pdate Incorporated into the ACC/AHA 2006 Guidelines for
e Management of Patients With Valvular Heart Disease”
r details (102). However, a few issues specific to renal
ansplantation candidates are highlighted below.
First, a large retrospective study of 35,215 patients on the
dney transplant waitlist in 1994 to 1997 suggested that
corrected valve disease is a barrier to transplantation (103).
pecifically, patients with value disease who did not undergo
rgical correction had lower rates of transplantation com-
red with patients without valve disease, whereas transplan-
tion rates were not reduced among patients with valve
sease who underwent pretransplantation valve surgery. In
dition, transplantation was associated with a reduction in
e risk for hospitalization for valvular heart disease.
Second, observational studies in the ESRD population
ve demonstrated an increased incidence of aortic and mitral
lve calcification, thought to be related to abnormalities of
lcium and phosphate metabolism (104). The increased rate
aortic stenosis progression is roughly twice normal, esti-
ated at 0.23 cm2/y compared with 0.05 to 0.1 cm2/y for the
neral population (12). This potentially classifies ESRD
tients with aortic stenosis in the subgroup with a high
kelihood of rapid progression, a subgroup that may be
nsidered for aortic valve replacement even in the absence
symptoms, according to the “2008 Focused Update of the pCC/AHA 2006 Guidelines for the Management of Patients
ith Valvular Heart Disease” (102). These guidelines in-
ude a Class IIb recommendation stating that aortic valve
placement “may be considered for adults with severe
ymptomatic aortic stenosis if there is a high likelihood of
pid progression (age, calcification, and CAD) or if surgery
ight be delayed at the time of symptom onset.” Emerging
search in the dialysis population has suggested that other
ctors such as neopterin (a marker of cellular immune
stem activation) may play a role in the rapid progression of
rtic stenosis (105). Although it remains to be determined
hether phosphate binders or anti-inflammatory medications
n reduce the rate of progression of aortic stenosis in ESRD
tients, it seems reasonable to monitor patients with ESRD
ith moderate or more severe aortic stenosis with an echo-
rdiogram at least once per year and to assess clinically for
mptoms.
Third, the increased prevalence of calcification in ESRD
tients mentioned in the last section may also affect mitral
lve function. The process of valvular calcification may
gin as mitral annular calcification with encroachment into
th mitral leaflets, leading to mitral regurgitation, mitral
enosis, or both. Assessing the clinical significance of this
enario may present a dilemma to the clinician because the
verity of mitral regurgitation may range from mild to severe
the basis of preload (volume status) and afterload (blood
essure). Thus, it is recommended that patients be evaluated
hen they are at their dry weight (immediately after dialysis
the intradialytic day) and with optimal hemodynamics
eart rate and blood pressure control) (12). Because this is a
rm of “functional” mitral regurgitation, some patients will
perience an improvement in severity with renal transplan-
tion (and concomitant improved volume management) even
the absence of mitral valve surgery (106).
Finally, if valve replacement is deemed necessary, the
eferred type of prosthetic valve (bioprosthetic versus me-
anical) is probably more dependent on traditional risk
ctors than the presence of ESRD. It is mostly of historical
terest that the 1998 “ACC/AHA Guidelines for the Man-
ement of Patients With Valvular Heart Disease” gave a
lass III recommendation (“conditions for which there is
idence and/or general agreement that the procedure is not
eful and in some cases may be harmful”) to placement of a
oprosthetic heart valve in patients with renal failure, hemo-
alysis, or hypercalcemia because of the risk of accelerated
ructural degeneration (107). Since that time, this warning
s been challenged and removed from the updated ACC/
HA valvular guidelines on the basis of multiple studies. One
udy of 5,858 dialysis patients who underwent valve replace-
ent (aortic, mitral, or both) in 1978 to 1998 reported no
fference in survival regardless of whether the patient re-
ived a bioprosthetic or mechanical valve (108). A
llow-up study by the same group of 1,335 kidney trans-
antation patients hospitalized in 1991 to 2004 for cardiac
lve replacement also reported no significant difference in
rvival regardless of bioprosthetic versus mechanical valve,
ith a trend favoring a bioprosthetic valve (2-year survival
tes: 61.5% for bioprosthesis, 59.5% for mechanical;0.30) (109). Design and production advances from the
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July 31, 2012:434–80 Cardiac Disease Evaluation and Management Among Transplantation Candidatesrst-generation bioprosthetic valves may make them more
sistant to rapid calcification in ESRD as was once feared,
d more recent studies have not demonstrated a survival
vantage for mechanical valves in these patient populations.
lthough some bioprosthetic valves claim a durability of 15
20 years, the true long-term durability of these valves in
SRD patients remains poorly defined. It is also unknown
w renal transplantation changes the natural history of
osthetic valves in patients with ESRD. In conclusion, data
ggest that bioprosthetic and mechanical valves appear to be
sociated with similar survival rates, and it is probably
asonable to choose the optimal prosthetic valve on the basis
other factors in accordance with the standard 2008 ACC/
HA valvular guidelines such as age, bleeding risk, and
dications/contraindications for warfarin.
ecommendation
It may be reasonable to consider ESRD patients with
moderate aortic stenosis to be equivalent to demon-
strated “rapid progressors” who warrant a yearly
echocardiogram and monitoring for early symptoms
(Class IIb; Level of Evidence C).
ulmonary Hypertension
he importance of pulmonary hypertension in patients con-
dered for liver transplantation is well known; however, the
gnificance for patients considered for renal transplantation
less clear. Several studies suggest that elevated pulmonary
essures are associated with adverse outcomes after renal
ansplantation. Among 255 kidney transplant recipients at 1
nter with reports from a preoperative echocardiogram that
cluded adequate evaluation of the pulmonary artery systolic
essure (PASP), Zlotnick et al. (110) reported PASP 35
m Hg in 38%. Specificities of PASP levels35 mm Hg and
45 mm Hg for prediction of a combined outcome of
layed or slow graft function were 56% and 80%, respec-
vely. The presence of an arteriovenous fistula and the
ount of time on dialysis correlated with the likelihood of
evated pulmonary pressures. In another study with data on
timated PASP by echocardiography in 215 potential renal
ansplantation candidates, estimated PASP 50 mm Hg was
sociated with an increased risk of post-transplantation death
R, 3.75; p0.016), and time on dialysis was the strongest
rrelate of an elevated PASP (111). Although further study
needed to confirm these findings, recent advances in the
armacological management of pulmonary hypertension
12) make this another possible area for risk reduction
fore renal transplantation.
From these observations, we suggest consideration of
rther evaluation of pulmonary hypertension among kidney
ansplantation candidates with echocardiographic evidence
right ventricular systolic pressure 45 mm Hg, the
reshold associated with post-transplantation outcomes in
servational studies to date (110,111), or with ancillary
idence of right ventricular pressure overload according to
e 2010 American Society of Echocardiography “Guidelines
r the Echocardiographic Assessment of the Right Heart in
dults” (113) such as right ventricular hypertrophy or a right
ntricular pressure overload pattern of interventricular septal Totion. Furthermore, because volume status may affect the
hocardiographic assessment of the right heart, the 2005
KF/KDOQI “Clinical Practice Guidelines for Cardiovascu-
r Disease in Dialysis Patients” recommend that echocardio-
ams be performed in all patients at the initiation of dialysis,
ce patients have achieved a dry weight (ideally within 1 to
months of dialysis initiation), and at the time of evaluation
r kidney transplantation (12).
ecommendations
It is reasonable to evaluate kidney transplantation
candidates with echocardiographic evidence of signifi-
cant pulmonary hypertension for underlying causes
(e.g., obstructive sleep apnea, left heart disease) (Class
IIa; Level of Evidence C).
It may be reasonable to confirm echocardiographic
evidence of elevated pulmonary arterial pressures in
kidney transplantation candidates by right heart cath-
eterization (Class IIb; Level of Evidence C). Echocar-
diographic evidence of significant pulmonary hyperten-
sion in this population is defined by right ventricular
systolic pressure more than 45 mm Hg or ancillary
evidence of right ventricular pressure overload.
If right heart catheterization confirms the presence of
significant pulmonary arterial hypertension (as defined
by mean pulmonary artery pressure >25 mm Hg,
pulmonary capillary wedge <15 mm Hg, and pulmo-
nary vascular resistance of >3 Wood units) in the
absence of an identified secondary cause (e.g., obstruc-
tive sleep apnea, left heart disease), referral to a
consultant with expertise in pulmonary arterial hyper-
tension management and advanced vasodilator thera-
pies is reasonable (Class IIa; Level of Evidence C).
ubclinical Myocardial Disease
he prognostic value of newer echocardiographic markers
ch as tissue Doppler and strain parameters was examined in
9 kidney transplantation candidates free of ischemia on
SE (114). Beyond traditional clinical predictors, abnormal
ssue Doppler findings improved the prediction of cardiovas-
lar events and mortality. Among the subgroup of patients
ho underwent renal transplantation, a significant improve-
ent in left ventricular wall thickness, left ventricular vol-
e, tissue Doppler velocity, and strain was noted after
ansplantation. In contrast, the same parameters worsened
er the same time period in patients who remained on
alysis. This suggests that untoward left ventricular struc-
ral changes occur on dialysis even when normal left
ntricular function is maintained and ischemia is absent on
aditional echocardiographic imaging.
vidence for Preoperative 12-Lead ECG in
idney Transplantation Candidates
ased on expert consensus, the ACC/AHA “Guidelines on
erioperative Cardiovascular Evaluation and Care for Non-
rdiac Surgery” (7) suggest that supplemental preoperative
rdiac evaluation includes an ECG and that the optimal
ming of this test is within 30 days of the planned surgery (7).
hese recommendations are based on several reports that
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Cardiac Disease Evaluation and Management Among Transplantation Candidates July 31, 2012:434–80ve studied the utility of the preoperative 12-lead ECG as a
edictor of adverse outcomes in both the general population
d in the renal transplantation population.
Although there is a paucity of data on the value of
eoperative ECG in the renal transplantation population,
ta are available on the natural history of baseline ECG
normalities in patients on dialysis, the relationship between
normal ECG findings at baseline and high-risk MPS results
patients with diabetes mellitus, and the value of exercise
CG in transplantation patients. Abe et al. (115) evaluated
utine 12-lead ECG findings in a consecutive series of 221
tients on long-term hemodialysis compared with patients
ith CKD not on dialysis and patients without kidney
sease. The prevalence of abnormal ECG findings was 65%,
%, and 5% for these 3 groups, respectively. Significant
fferences between the patients on dialysis and the normal
ntrol subjects included left ventricular hypertrophy (19%
rsus 0.7%), evidence of ischemia (7.2% versus 0.6%),
emature ventricular contractions (6.8% versus 0.3%), non-
ecific ST-T changes (6% versus 0.3%), atrial fibrillation
.4% versus 0%), left atrial enlargement (2.7% versus 0%),
d old MI (1.4% versus 0%). In addition, 87 hemodialysis
tients were followed for a mean of 7.5 years with serial
CGs. With respect to ECG findings, 39% remained normal
roughout the monitored period, 31% were considered ab-
rmal but stable, 25% had worsening of their ECG findings,
d 5% had apparent improvement.
Rajagopalan et al. (116) studied the correlation of ECG
ndings with MPS results in 1738 asymptomatic patients
ith diabetes mellitus who were free of known CAD. The
esence of Q waves on ECG was the strongest independent
rrelate of abnormal high-risk MPS results (OR, 3.92).
ixty-one percent of patients with high-risk MPS results were
und to have angiographic evidence of left main CAD,
vessel CAD, or 1- or 2-vessel CAD with proximal left
terior descending artery disease.
In summary, it seems reasonable to obtain a baseline ECG
all renal transplantation candidates given the low cost and
e predictive value of abnormal ECG findings for overall
sk stratification. It is worth noting, however, that the
evalence of abnormal ECG findings is higher among
tients with advanced kidney failure than in the general
pulation. The high prevalence of some abnormalities (i.e.,
ft ventricular hypertrophy) may decrease the utility of
andard ECG treadmill testing in patients with kidney
ilure. Serial changes on ECG in hemodialysis patients can
expected over time, and periodic monitoring of ECGs
.g., annually) while on a transplant waitlist may be appro-
iate, although there are no data to support a firm recom-
endation on an optimal time interval between ECG tests.
ecommendations
A preoperative resting 12-lead ECG is recommended
for potential kidney transplantation candidates with
known coronary heart disease, known peripheral arte-
rial disease, or any cardiovascular symptoms (Class I;
Level of Evidence C). unA preoperative resting 12-lead ECG is reasonable in
potential kidney transplantation candidates without
known cardiovascular disease (Class IIa; Level of
Evidence C).
Annual performance of 12-lead ECG after listing for
kidney transplantation may be reasonable (Class IIb;
Level of Evidence C).
iomarkers as Tools for Cardiac Evaluation in
idney Transplantation Candidates
utative applications of biomarkers such as cardiac troponins
Tns) in kidney transplantation candidates include risk
ratification within protocols for initial disease screening,
rveillance after listing, and as a reference against which to
mpare levels if symptoms of an acute coronary syndrome
ise. Risk stratification of asymptomatic patients with bio-
arkers is distinct from the diagnosis of acute coronary
ndromes. Although cTns are excreted by the kidney, the
urce of elevations in the bloodstream even in patients with
SRD appears to be the myocardium. A dynamic rise and fall
cTn with appropriate clinical signs or symptoms suggests
acute coronary syndrome, but persistent elevations in cTn
ay result from other sources of prognostically important
rdiac stress such as volume overload, uncontrolled hyper-
nsion, or left ventricular hypertrophy (117). Persistent
evations of cTnT isoform levels correlate with all-cause and
rdiac mortality in asymptomatic patients on dialysis. A
eta-analysis of 28 studies found that cTnT 0.10 ng/mL in
tients with ESRD predicts more than twice the mortality
sk of patients with ESRD with lower cTnT levels (118). The
ognostic value of cTnI isoform levels has been less consis-
nt, perhaps because of a lack of assay standardization and/or
e of a broader range of threshold values in studies to date.
ased on such data, the Food and Drug Administration
proved the use of cTnT levels for mortality prognostication
patients with chronic renal failure in 2004. However,
utine use has not yet been supported by the NKF/KDOQI
idelines (12).
Associations of cTnT with mortality before and after
dney transplantation (Table 6) have also been studied.
oncomitant elevations of cTnT 0.06 ng/mL and ischemia-
odified albumin 95 kU/L measured in a cohort of 144
tential transplantation candidates were associated with 7
es the odds of mortality after an average of 2.3 years, with
justment for factors including severe coronary disease and
sults from positive DSE (119). Hickson et al. (61) studied 644
tential transplantation candidates and found that each incre-
ent in cTnT level (0.01, 0.01–0.03, 0.04–0.09, and 0.10
/mL) was associated with 64% higher adjusted relative risk
transplantation-censored mortality. cTnT measured before
ansplantation also predicted post-transplantation cardiac
ents and death (121). Over a mean follow-up of 28 months,
ch increment in cTnT was associated with 58% higher
lative risk of MACEs after transplantation. Another study
ported that mortality at 3.8 years of follow-up was nearly 3
mes higher in patients with cTnT 0.03 versus 0.01
/mL (120). Although this finding is intriguing, it remains
certain how data from biomarker assessment should be
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ansplantation.
ecommendation
Measurement of cTnT level at the time of evaluation
for kidney transplantation may be considered an ad-
ditional prognostic marker (Class IIb; Level of Evi-
dence B).
vidence for Cardiac Computed Tomography
Kidney Transplantation Candidates
oncontrast computed tomography (CT) for the detection
d quantification of coronary artery calcification has been
own to improve cardiovascular risk prediction compared
ble 6. Summary of Recent Studies of Associations of Cardiac
ndidates and Recipients
Authors, Year Design and Data Source Participants and Selection
arma et al. (119),
06
Prospective cohort
Medical records and phone
calls for follow-up
114 evaluated for KT
candidacy at 1 center in
the United Kingdom
(2002–2003)
Free of unstable angina or
severe aortic stenosis
nnolly et al. (120),
08
Prospective cohort
Registry mortality data and
phone calls for follow-up
Convenience sample of
379 with functioning KT at
2 Irish hospitals 3 mo
after KT and well at
enrollment (2000–2002)
ckson et al. (61),
08
Retrospective cohort
Clinical records of 1 center
644 evaluated for KT
candidacy at 1 Midwestern
center (2004–2006)
ckson et al. (121),
09
Retrospective cohort
Clinical records of 1 center
603 evaluated for KT
candidacy at 1 Midwestern
center (2004–2007)
aHR indicates adjusted hazards ratio; AMI, acute myocardial infarction; aOR
sease; CI, confidence interval; cTnT, cardiac troponin T; DSE, dobutam
hemia-modified albumin; KT, kidney transplantation; MACEs, major adverse
Reproduced from Lentine et al. (62) with permission from Elsevier. Copyrighith the FHS score in asymptomatic patients without kidney casease (122). Raggi et al. (123) found evidence of elevated
T calcium scores in 83% of a sample of 205 adult
aintenance hemodialysis patients, and other studies have
ported significantly greater intracoronary calcification in
tients with ESRD compared with patients without ESRD,
ith the greatest disparities in young cohorts (124–126).
lthough 1 study reported CT calcium scores to be an
dependent predictor of death in patients on long-term
modialysis (127), the role of CT calcium scoring as a
ognostic marker in the ESRD population is uncertain (128).
ther studies report poor correlation between coronary artery
lcium scores and the likelihood of angiographic CAD in
tients with advanced kidney disease (129–131), a finding
at may reflect the high burden of medial vascular calcifi-
rkers With Clinical Outcomes in Kidney Transplantation
dy Measures and
Distributions Clinical Outcomes Associations/Effect Sizes
cTnT level;
tion 0.06 ng/mL,
IMA level;
tion 95 KU/L,
nd IMA were both
d in 33%
Death over observation
(multivariate modeling by
logistic regression and thus
not time dependent)
After mean 2.3 y of follow-
up, 15.8% died (55.6% of
deaths were cardiovascular)
Combined cTnT and IMA
elevations significantly
associated with 7 times
the odds of death (aOR,
7.12; 95% CI, 4.14 to
10.12; p0.005)
compared with normal
levels of both markers
after adjustment,
including severe CAD
and positive DSE
cTnT and IMA
individually associated
with mortality in
bivariate but not
multivariate models
cTnT level
tion: 0.01 ng/mL,
0.02 ng/mL, 2.7%;
ng/mL, 5.6%
Death over observation
After median 3.8 y of follow-
up, 16.4% died (39% of
deaths were cardiovascular)
cTnT 0.03 versus
0.01 significantly
associated with 2.7
times the risk of death
(aHR, 2.70; 95% CI,
1.20 to 6.06; p0.02)
after adjustment,
including eGFR and
C-reactive protein levels
cTnT level analyzed,
cent from initial
ion or annual
up if waitlisted
tion across
s: 0.01 ng/mL,
.01–0.03 ng/mL,
.04–0.09 ng/mL,
0.10 ng/mL, 13%
Death, censored at KT or
December 2007
After median 6.2 mo of
follow-up, 5.4% died (33% of
known causes were
cardiovascular), and 58.5%
received KT
Each increment in cTnT
level (as defined)
significantly associated
with 64% increase in
death risk (aHR, 1.64;
95% CI, 1.07 to 2.51;
p0.02)
cTnT level analyzed,
cent from initial
ion or annual
up if waitlisted
tion across
s:0.01 ng/mL,
0.01–0.03 ng/mL,
0.04–0.09 ng/mL,
0.10 ng/mL,
All-cause death or MACEs
(AMI, CABG or PCI) after KT,
censored at graft loss
After a mean 28 mo of
follow-up, 5.6% reached the
endpoint (including death in
4%)
Each increment in cTnT
level (as defined)
significantly associated
with 58% increase in
the composite end point
(aHR, 1.58; 95% CI,
1.13 to 2.23; p0.008)
d odds ratio; CABG, coronary artery bypass grafting; CAD, coronary artery
ss echocardiography; eGFR, estimated glomerular filtration rate; IMA,
scular events; and PCI, percutaneous coronary intervention.
American Kidney Foundation.Bioma
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4–320 slice and dual source) is a highly sensitive tool for
aluating symptomatic patients with low to intermediate
etest probability of obstructive CAD (133,134). However,
is modality has not been studied in patients with significant
dney disease, and its accuracy may be limited in this
pulation because of a high burden of calcified coronary
herosclerosis. Furthermore, safety may be limited in pa-
ents with kidney disease by the attendant exposure
iodinated contrast. The “ACCF/SCCT/ACR/AHA/ASE/
SNC/NASCI/SCAI/SCMR 2010 Appropriate Use Criteria
r Cardiac Computed Tomography” consider CT angiogra-
y a potential option among patients undergoing heart
rgery for noncoronary indications (e.g., valve replacement
rgery or atrial septal defect closure) when the pretest CAD
sk is either intermediate (appropriate) or low (uncertain) but
em that there are no appropriate indications for coronary
T angiography as part of the preoperative evaluation for
ncardiac surgery (135). The usefulness of noncontrast CT
lcium scoring and cardiac CT angiography is uncertain for
e assessment of pretransplantation cardiovascular risk.
ecommendation
The usefulness of noncontrast CT calcium scoring and
cardiac CT angiography is uncertain for the assess-
ment of pretransplantation cardiovascular risk (Class
IIb; Level of Evidence B).
vidence on Prophylactic Coronary
evascularization to Reduce
erioperative Cardiac Complications
here is a significant gap in the literature in terms of the
tcomes of prophylactic coronary revascularization in the
nal transplantation candidate population. Only 1 small
ndomized trial and a few observational studies have fo-
sed on this patient population. In 1992, Manske et al. (136)
ndomly assigned 31 transplantation candidates with insulin-
pendent diabetes mellitus with CAD (75% stenosis) to
vascularization or medical therapy with a calcium channel
ocker and aspirin. Ultimately, 10 of 13 medically managed
d 2 of 13 revascularized patients reached the endpoint
mprising unstable angina, MI, or cardiac death. Contem-
rary relevance of these findings is limited by the small
mple size, high event rate among the medically managed
oup, and advances that have occurred in “standard” medical
anagement of CAD, including the use of angiotensin-
nverting enzyme inhibitors and statins.
Several observational studies have reported outcomes after
ronary revascularization in selected cohorts of potential
dney transplantation candidates. In a study of 300 patients
ho underwent multimodality testing as part of the candidate
aluation at 1 center, crude survival was not different in
tients who underwent revascularization compared with
ose who underwent angiography without revascularization
no angiography, although there was a suggestion of a
nefit with revascularization in the subset of 34 patients
und to have obstructive CAD (15% versus 52% mortality) di8). In the description of 3698 patients evaluated for kidney
ansplantation at a single center by Hage et al. (60), MPS was
rformed in 60%, and 7% of the patients subsequently
derwent coronary angiography. The presence and severity
CAD on angiography were not predictive of survival
able 4), and coronary revascularization was associated with
rvival only in patients with 3-vessel CAD.
A recent study described the experience at 1 center under
protocol in which all potential kidney transplantation
ndidates were evaluated by angiography for any of the
llowing criteria: age 50 years, diabetes mellitus, any
rdiac symptoms, or ECG evidence of ischemia or prior
farction (137). Among the 657 patients who underwent
giography in 2006 to 2009, significant CAD (defined as
75% stenosis of 1 or more coronary arteries, 50% left
ain stem lesion, or an equivocal lesion with flow limitation)
as found in 28%, of whom 55% were free of symptoms and
ior CAD history. Those with significant CAD who under-
ent revascularization followed by transplantation (n51;
year survival, 100%; 3-year survival, 97%) or by continued
aiting (n177; 1-year survival, 95%; 3-year survival, 81%)
d survival superior to that of the 16 patients who declined
vascularization (1-year survival, 75%; 3-year survival,
%). Although this study demonstrates excellent survival in
ansplant recipients who received preemptive revasculariza-
on, the lack of a comparator group of similar patients who
d not undergo angiography before transplantation prevents
nclusions on the impact of the authors’ approach compared
ith a less aggressive strategy. Further data on the potential
nefits of prophylactic revascularization are based on ex-
apolation of a prophylactic revascularization strategy in
her high-risk groups such as patients undergoing vascular
rgery and patients with diabetes mellitus as discussed
low.
oronary Artery Revascularization
rophylaxis (CARP) Trial
he potential benefits of coronary revascularization before
ncardiac surgery were evaluated in the CARP (Coronary
rtery Revascularization Prophylaxis) trial. Patients awaiting
scular surgery (n510) with concomitant CAD on coro-
ry angiography (excluding those with left main disease or
verely depressed LVEF [20%]) were randomized to
ABG (59%) or PCI (41%) versus optimal medical therapy
fore vascular surgery (10). At 2.7 years after randomiza-
on, mortality in the coronary revascularization group was
t significantly different (22%) from that in the no-
vascularization group (23%). Within 30 days after the
scular operation, a postoperative MI, defined by elevated
n levels, occurred in 12% of the revascularization group
d 14% of the no-revascularization group (p0.37). The
thors concluded that preoperative coronary revascularization
not indicated in patients with stable CAD who are on optimal
edical therapy. Although patients with unprotected left main
AD were excluded from randomization, retrospective analysis
this subset (who made up 4.6% of the 1,048 patients assessed
preoperative coronary angiography) suggested improved
rvival with versus without revascularization of left main
sease CAD before vascular surgery (138).
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valuation Applying Stress Echocardiography V
ECREASE-V)
he potential benefits of screening and coronary revascular-
ation before noncardiac surgery have also been evaluated in
e DECREASE-V (Dutch Echocardiographic Cardiac Risk
valuation Applying Stress Echocardiography V) pilot study
). Among 1,880 patients scheduled for major elective
scular surgery, those (n430) with 3 risk markers (age
70 years, angina pectoris, MI, heart failure, stroke, diabetes
ellitus, renal failure) underwent stress imaging with DSE or
PS. Patients (n101) with extensive stress-induced isch-
ia were randomly assigned to additional coronary revascu-
rization or medical therapy only. Prophylactic coronary revas-
larization in vascular surgery patients with extensive ischemia
as not associated with an improved immediate postoperative
tcome (9) or with survival over 2.8 years (11).
linical Outcomes Utilizing Revascularization
nd Aggressive Drug Evaluation (COURAGE)
OURAGE (Clinical Outcomes Utilizing Revascularization
d Aggressive Drug Evaluation) was a randomized trial of
87 people in the United States and Canada that evaluated
hether PCI plus optimal medical therapy (beta-blockers,
lcium channel blockers, and nitrates) reduces the risk of
l-cause mortality or nonfatal MI in patients with stable
AD (70% stenosis in at least 1 proximal epicardial
ronary artery and objective evidence of myocardial isch-
ia) compared with optimal medical therapy alone (29).
KD was not an exclusion for enrollment. The primary
alysis revealed no differences among the PCI group and the
edical therapy alone group in the composite endpoint
eath, MI, or stroke) or in MI alone over a median 4.6 years
follow-up. Secondary analysis of 320 participants with
KD defined as eGFR 60 mL/min/1.73 m2 demonstrated
at, although CKD was associated with an increased risk of
ath or nonfatal MI over 36 months (adjusted HR, 1.48; 95%
I, 1.15 to 1.90), the incidence of death or MI was similar in
tients with CKD treated with PCI and medical therapy
mpared with those treated with medical therapy alone (30).
dditional subgroup analyses also did not support benefit of
CI compared with optimal medical management on the
imary endpoint in subgroups of individuals with diabetes
ellitus, patients with multivessel CAD or those with prior
I (29). From the results of the COURAGE trial, PCI is
dicated for mitigating medically refractory symptoms but
t for preventing MI or cardiac death in stable patients.
The role of preoperative PCI in reducing untoward periop-
ative cardiac complications appears limited to patients with
stable active CAD who would be appropriate for emergent
urgent revascularization under the published ACC/AHA/
CAI PCI guidelines (139,140,141a). Patients with ST-
gment elevation MI or those with unstable angina and
n–ST-segment elevation MI benefit from early invasive
anagement, as outlined in the “2011 ACCF/AHA Focused
pdate Incorporated Into the ACC/AHA 2007 Guidelines for
e Management of Patients With Unstable Angina/Non-ST-
levation Myocardial Infarction” (140) and the “2011 ACC/ coHA/SCAI Guideline for Percutaneous Coronary Interven-
on” (141a). PCI has been shown to reduce the incidence of
gina, not to improve survival in stable patients; PCI may
crease the short-term risk of MI and does not lower the
ng-term risk of MI.
Patients with asymptomatic ischemia or stable angina
table ischemic heart disease) do not appear to benefit from
ophylactic preoperative coronary revascularization unless
rdiac catheterization reveals high-risk anatomy in which
vascularization would result in a survival advantage. The
atomic subsets and revascularization strategies that confer
survival advantage are discussed in detail in the “2011
CCF/AHA Guideline for Coronary Artery Bypass Graft
urgery” and “2011 ACCF/AHA/SCAI Guideline for Per-
taneous Coronary Intervention” developed in conjunc-
on with the Stable Ischemic Heart Disease and the
ercutaneous Coronary Intervention Guideline Writing
ommittees (31a,141a). These recommendations are sum-
arized in Table 7.
High-risk unprotected left main CAD in a noncardiac
rgical candidate is a special case. The issues involved in
se selection and risk stratification for revascularization of
ft main CAD are discussed in detail in the “2011 ACCF/
HA Guideline for Coronary Artery Bypass Graft Surgery”
1a). The utility of a PCI left main revascularization strategy
the context of impending transplantation is unknown. In
rms of durability of result and the need for prolonged dual
tiplatelet therapy, CABG remains the revascularization
ocedure of choice, if appropriate, for prospective transplan-
tion patients with left main or left main–equivalent CAD.
In conclusion, in patients with stable CAD, the indications
r CABG and PCI in the preoperative setting should be
entical to those developed by the harmonized ACCF/AHA
ABG and ACCF/AHA/SCAI PCI revascularization guide-
nes (31a,141a). There is no evidence to support prophylactic
eoperative percutaneous revascularization in patients with
ymptomatic ischemia or stable angina.
CI Versus CABG in
atients With ESRD
he best method of coronary revascularization in patients
ith ESRD is controversial. Szczech et al. (142) examined
ew York State Health Department data for patients who
ceived CABG surgery or PCI in 1993 to 1995 to study
rvival after revascularization procedures in patients with
KD (serum creatinine 2.5 mg/dL) or ESRD. Among
tients with ESRD, CABG was associated with a 61%
lative mortality reduction compared with PCI (RR, 0.39;
% CI, 0.22 to 0.67) after adjustment for severity of CAD
ft ventricular dysfunction, and other comorbid conditions.
survival benefit of CABG over PCI was seen in all CAD
atomic subgroups. An analysis of the Duke cardiac revas-
larization database found a graded relationship between
nal insufficiency and increased mortality compared with
tients with normal renal function (143). Among patients
ith estimated creatinine clearance 15 mL/min/1.73 m2 or
dialysis, CABG was associated with a survival benefit
mpared with medical management (adjusted HR, 0.45;
Ta
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Anatomic Setting Class of Recommendation
Level of
Evidence
LM or complex CAD
CABG and PCI I: Heart team approach recommended C
CABG and PCI IIa: Calculation of the STS and SYNTAX scores B
LM*†
CABG I B
PCI IIa: For SIHD when both of the following are present B
Anatomic conditions associated with a low risk of PCI procedural complications and high
likelihood of good long-term outcome (e.g., a low SYNTAX score of 22, ostial or trunk
left main CAD)
Clinical characteristics that predict a significantly increased risk of adverse surgical
outcomes (e.g., STS-predicted operative mortality 5%)
IIa: For UA/NSTEMI if not CABG candidate B
IIa: For STEMI when distal coronary flow is less than TIMI 3 and PCI can be performed
more rapidly and safely than CABG
C
IIb: For SIHD when both of the following are present B
Anatomic conditions associated with a low to intermediate risk of PCI procedural
complications and intermediate to high likelihood of good long-term outcome (e.g., low
to intermediate SYNTAX score of 33, bifurcation left main CAD)
Clinical characteristics that predict an increased risk of adverse surgical outcomes (e.g.,
moderate to severe COPD, disability from prior stroke, or prior cardiac surgery; STS-
predicted operative mortality 2%)
III, harm: For SIHD in patients (versus performing CABG) with unfavorable anatomy for PCI
and who are good candidates for CABG
B
Vessel disease with or without proximal LAD disease*†
CABG I B
IIa: It is reasonable to choose CABG over PCI in patients with complex 3-vessel CAD (e.g.,
SYNTAX 22) who are good candidates for CABG
B
PCI IIb: Of uncertain benefit C
Vessel disease with proximal LAD disease*†
CABG I B
PCI IIb: Of uncertain benefit C
Vessel disease without proximal LAD disease*†
CABG IIa: With extensive ischemia B
IIb: Of uncertain benefit without extensive ischemia C
PCI IIb: Of uncertain benefit C
ngle-vessel proximal LAD disease†
CABG IIa: With LIMA for long-term benefit B
PCI IIb: Of uncertain benefit C
ngle-vessel disease without proximal LAD involvement†
CABG III, harm B
PCI III, harm B
dysfunction
CABG IIa: EF 35%–50% B
CABG IIb: EF 35% without significant left main CAD B
PCI Insufficient data
dden cardiac death survivors with presumed ischemia-mediated VT caused by ischemia
CABG I B
PCI I C
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; EF, ejection fraction; LAD, left anterior
scending; LIMA, left internal mammary artery; LV, left ventricular; NSTEMI, non–ST-segment elevation myocardial infarction; PCI, percutaneous coronary
tervention; SIHD, stable ischemic heart disease; STEMI, ST-elevation myocardial infarction; STS, Society of Thoracic Surgeons; SYNTAX, Synergy Between
rcutaneous Coronary Intervention With Taxus and Cardiac Surgery; TIMI, Thrombolysis in Myocardial Infarction; UA, unstable angina; UPLM, unprotected left main
sease; and VT, ventricular tachycardia.
*In patients with multivessel disease who also have diabetes mellitus, it is reasonable to choose CABG (with LIMA) over PCI (Class IIa, Level of Evidence B).
†Revascularization (CABG or PCI) might be reasonable to improve survival in patients with chronic kidney disease (creatine clearance 60 mL/min), with CABG
sociated with a greater benefit than PCI among patients with more advanced renal dysfunction (Class IIb, Level of Evidence B).Reproduced from Hillis et al. (31a) with permission of the American Heart Association. Copyright 2010, American Heart Association, Inc.
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onal studies have demonstrated improved survival with
ABG (compared with medical therapy) in patients with
KD and multivessel CAD (144).
A retrospective study of dialysis patients captured in the
SRDS before the widespread use of drug-eluting stents
ES) suggested a slight long-term benefit of CABG over
CI. However, these data are limited by the retrospective
sign and the inherent risk of procedure-related referral bias
sed on coronary anatomy and patient characteristics (145).
n updated analysis of USRDS data from 2003 to 2005 by
e same authors, including patients treated with DES, found
perior 12-month unadjusted postprocedural survival in
tients on dialysis who received DES (69.7%) compared
ith CABG (66.6%) or non-DES PCI (63.6%) (146). How-
er, unadjusted 36-month survival favored CABG over DES
2.0% versus 38.1%), especially among patients who re-
ived an internal mammary artery bypass conduit. In mul-
variable regression, there was no significant difference in
erall adjusted mortality with DES versus bypass, although
n-DES PCI was associated with a higher adjusted risk
mpared with surgery. These data also demonstrate the poor
ognosis faced by patients on hemodialysis who undergo
ABG compared with the 5-year survival after CABG in the
neral population of 85% to 90% (31). Other studies have
ported increased frequencies of surgical complications,
cluding mediastinitis, stroke, and prolonged mechanical
ntilation, after CABG in patients with ESRD compared
ith patients without ESRD (147).
CI Versus CABG in Patients With
iabetes Mellitus
arge randomized studies of revascularization in renal trans-
antation candidates with diabetes mellitus are lacking, but
me insight can be gained from the extensive study of the
anagement of CAD in patients with diabetes mellitus
ithout advanced renal failure. Several trials have addressed
e question of the relative benefit of CABG versus PCI in
tients with diabetes mellitus with CAD.
A pooled analysis of coronary revascularization trials in
tients with diabetes mellitus published in 2005 (148)
cluded 6 randomized clinical trials comparing CABG with
CI among 950 patients with diabetes mellitus. A mortality
nefit of CABG over balloon-only PCI at 3 to 5 years was
nsistently noted. Use of stents narrowed the mortality
vantage of CABG, but higher rates of repeat revasculariza-
on were seen with stent PCI compared with CABG, even
ith DES. Another recent meta-analysis summarized data
mparing CABG and PCI among 7,812 patients from 10
inical trials demonstrated similar findings (149).
Registry data also support a survival advantage of CABG
er PCI in patients with diabetes mellitus with severe
ultivessel CAD. A report from the Northern New England
ardiovascular Study Group identified 10,198 CABG pa-
ents and 4,293 PCI patients with multivessel CAD in a
ARI (Bypass Angioplasty Revascularization Investigation)–
ke cohort (150). Adjusted long-term survival for patients
ith 3-vessel CAD was better after CABG than PCI (HR, A60; p0.01) but not for patients with 2-vessel CAD (HR,
98; p0.77). Survival advantage with CABG for patients
ith 3-vessel disease was present in all subgroups, includ-
g women, the elderly, and individuals with diabetes
ellitus.
ecommendations for
eferral to a Cardiologist
lthough a relationship of the organizational structure of the
nsulting cardiology service with clinical outcomes has not
en formally evaluated, it is reasonable that each program
tempt to identify a primary cardiology consultant for
estions related to potential transplantation candidates.
ecommendations
Referral criteria: Kidney transplantation candidates
who have an LVEF less than 50%, evidence of ischemic
left ventricular dilation, exercise-induced hypotension,
angina, or demonstrable ischemia in the distribution of
multiple coronary arteries should be referred to a
cardiologist for evaluation and long-term management
according to ACC/AHA guidelines for the general
population (Class I; Level of Evidence B).
Coordination of care: It may be reasonable for each
program to identify a primary cardiology consultant
for questions related to potential kidney transplanta-
tion candidates (Class IIb; Level of Evidence C).
Among the issues that should be managed by a cardiologist
perienced in pretransplant evaluations is minimization of
e risk of contrast-induced acute injury, if coronary angiog-
phy or PCI are indicated. The risk of contrast-induced acute
dney injury is inversely related to a patient’s eGFR (150a)
d is of particular concern in patients with stages 4 and 5
KD because of the potential for accelerating the need for
alysis. Other clinical and periprocedural risk factors for
ntrast-induced nephropathy include diabetes mellitus, in-
avascular volume depletion, hemodynamic instability, con-
mitant use of nephrotoxic drugs, and high contrast loads
50a,150b). Recent small, retrospective studies have sug-
sted that minimization of the risk of contrast-induced acute
dney injury from coronary angiography among kidney
ansplantation candidates may be possible with careful pa-
ent selection and careful management before, during, and
ter the procedure (150c,150d). However, the risk contrast-
duced acute kidney injury after pretransplant coronary
giography has not been evaluated in prospective studies
ith large numbers of patients and control groups.
ecommendations for Coronary
evascularization and Related Care
efore Kidney Transplantation
vidence-based indications for coronary revascularization in
e general population are based on improving survival or
mptoms. The “2011 ACCF/AHA Guideline for Coronary
rtery Bypass Graft Surgery” (31a) (Table 7) recommends
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Cardiac Disease Evaluation and Management Among Transplantation Candidates July 31, 2012:434–80at decisions on coronary revascularization be based on a
owledge of symptoms, ischemic burden, coronary anat-
y, complexity of CAD and cardiac function, and the
lative risks and benefits of guideline-directed medical
erapy, CABG, and PCI. These criteria define patients in
hom revascularization is indicated for either symptom relief
survival advantage, regardless of the need for noncardiac
rgery.
When PCI is considered for any patient who is a candidate
r transplantation, the durability of the result should be a
imary consideration, and avoiding repeat procedures in-
lving radiographic contrast administration is desirable. In
ansplantation candidates with diabetes mellitus in particular,
appears that elective revascularization with CABG offers
perior outcomes compared with PCI. CABG is the pre-
rred method of revascularization in patients with diabetes
ellitus with left main, 3-vessel CAD, and 2-vessel CAD
volving the proximal left anterior descending artery and should
strongly considered in terms of durability and the reduced
cidence of recurrent revascularization procedures in all trans-
antation candidates needing coronary revascularization.
ecommendations
Coronary revascularization before transplantation surgery
should be considered in patients who meet the criteria
outlined in the “2011 ACCF/AHA Guidelines for Cor-
onary Artery Bypass Graft Surgery” (Class I; Level of
Evidence B). It is recognized that in some asymptom-
atic transplantation candidates, the risk of coronary
revascularization may outweigh the risk of transplanta-
tion and these risks must be weighed by the multidisci-
plinary transplantation team on a case-by-case basis until
further studies are performed in this population.
CABG is probably recommended in preference to PCI
to improve survival in patients with multivessel CAD
and diabetes mellitus (Class IIa; Level of Evidence B).
CABG to improve survival and/or to relieve angina
despite optimal medical therapy may be reasonable for
patients with ESRD with significant (>50%) left main
stenosis or significant (>70%) stenoses in 3 major
vessels or in the proximal left anterior descending
artery plus 1 other major vessel, regardless of left
ventricular systolic function (Class IIb; Level of Evi-
dence B).
It is not recommended that routine prophylactic coro-
nary revascularization be performed in patients with
stable CAD, absent symptomatic or survival indica-
tions, before transplantation surgery (Class III; Level
of Evidence B).
terval Between PCI and
ubsequent Surgery
he need for noncardiac surgery in patients who have
dergone recent PCI is a common dilemma. After balloon
gioplasty, delaying noncardiac surgery for very long in-
eases the chance that restenosis at the angioplasty site will
ve occurred and theoretically increases the chances of
rioperative ischemia or MI. However, performing the cargical procedure too soon after the PCI procedure is also
zardous. Arterial recoil and/or acute thrombosis at the site
balloon angioplasty are most likely to occur within hours
days after balloon coronary angioplasty. Delaying surgery
r at least 4 to 6 weeks after balloon angioplasty to allow
aling of the vessel injury at the balloon treatment site is
pported by observational data (151). Daily antiplatelet
erapy should be continued perioperatively. The risk of
opping the aspirin must be weighed against the benefit of
wering the risk of bleeding complications from the planned
rgery.
If a coronary stent was used in the revascularization
ocedure, as in the majority of percutaneous revasculariza-
on procedures, further delay of noncardiac surgery may be
neficial. Bare-metal stent (BMS) thrombosis is most com-
on in the first 2 weeks after stent placement and is
ceedingly rare (0.1% of most case series) 4 weeks after
ent placement (152,153). Given that stent thrombosis will
ten result in Q-wave MI or death when it occurs and given
at the risk of BMS thrombosis diminishes after endotheli-
ization of the stent has occurred, it appears reasonable to
lay elective noncardiac surgery for 3 months, to allow at
ast partial endothelialization of the BMS, but not for 6
onths, when restenosis may occur.
Timing surgery after DES placement presents a greater
allenge. There appears to be a compelling need for pro-
nged dual antiplatelet medication to prevent stent thrombo-
s, usually aspirin 81 to 162 mg daily and a thienopyridine
lopidogrel 75 mg daily, ticlopidine 250 mg twice daily, or
asugrel 10 mg daily).
Two retrospective studies from the Mayo Clinic analyzed
e risk of cardiac complications after noncardiac surgery
the 2 years after BMS and DES implantation (154,155). There
as a temporal relationship between the frequency of
ACEs (death, MI, stent thrombosis, repeat revasculariza-
on) and the time since BMS implantation (30 days,
.5%; 30 to 90 days, 3.8%; and 90 days, 2.8%) (154). The
thors concluded that noncardiac surgery should be delayed
r 90 days after BMS placement. In a companion study of
0 patients undergoing noncardiac surgery after DES im-
antation, the authors found that the rate of MACEs was
west beyond 1 year after DES implantation (155).
A retrospective single-center observational study from The
etherlands identified 550 patients (376 DES, 174 BMS) who
derwent noncardiac surgery after coronary stent placement
56). The authors found an inverse relation between the
terval from PCI to noncardiac surgery and perioperative
ACEs. In the PCI BMS group, the rate of MACEs during
e intervals of 30 days, 30 days to 3 months, and 3
onths was 50%, 14%, and 4%, respectively (overall
0.001). In the PCI DES group, the rate of MACEs changed
gnificantly with the interval after PCI over a longer time
ame: 35%, 13%, 15%, 6%, and 9% for patients undergoing
ncardiac surgery within 30 days, 30 days to 3 months, 3
6 months, 6 to 12 months, and 12 months, respectively
verall p0.001).
An additional retrospective observational study from the
leveland Clinic addressed the risk of surgery, including
rdiac surgery, after DES placement (157). The primary
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obable stent thrombosis (158). Among 606 surgeries in 481
tients, the mean interval from stent placement to noncar-
ac surgery was 1.070.89 years. Stent thrombosis occurred
ter 2.0% of surgeries and a combined endpoint of death, MI,
stent thrombosis after 9% of surgeries. The risk of either
dpoint declined significantly in the first 1 to 6 months after
ent placement; however, the risk did not disappear even
ter 12 months. Independent correlates of the combined
dpoint were emergency surgery, prior MI, preoperative
parin, and stent length. Antiplatelet therapy was not an
dependent correlate of risk. The authors concluded that
ere is a significant risk of stent thrombosis and MACEs
ithin 30 days of DES placement, with 1% to 2% risk
tending to 2 to 3 years.
ntiplatelet Therapy in the
ontext of Recent PCI
general, treatment with dual antiplatelet agents is recom-
ended for a minimum of 1 month after BMS implantation
d for 12 months after DES implantation. Premature
scontinuation of antiplatelet agents is one of the strongest
edictors of subacute stent thrombosis. Thus, gauging the
sk of stent thrombosis in patients who require noncardiac
rgery and are taking dual antiplatelet agents after PCI is
portant.
The optimal duration of clopidogrel therapy beyond 1 year
s not been established and should depend on the physi-
an’s judgment of the risk-to-benefit ratio for the individual
tient. Expert opinion suggests that continuation of thien-
yridine (clopidogrel) therapy beyond 1 year may be con-
dered in higher-risk patients undergoing DES placement.
The 2007 AHA/ACC/SCAI/ACS/ADA Science Advisory
the “Prevention of Premature Discontinuation of Dual
ntiplatelet Therapy in Patients With Coronary Artery
tents” concluded that premature discontinuation of dual
tiplatelet therapy markedly increases the risk of catastrophic
ent thrombosis and death and/or MI (159) (Table 8). Consider-
ion should be given to continuing dual antiplatelet therapy
the perioperative period for any patient needing noncardiac
rgery that falls within the time frame of recommended
erapy, particularly those who have received DES. In addi-
on, consideration should be given to continuing dual anti-
atelet therapy perioperatively beyond the recommended
me frame in any patient thought to be at high risk for the
nsequences of stent thrombosis, such as patients in whom
evious stent thrombosis has occurred and in those after left
ain stenting, multivessel stenting, or stent placement in the
ly remaining coronary artery or graft conduit. Even after
ienopyridines have been discontinued, serious consider-
ion should be given to continuation of aspirin therapy
rioperatively in any patient with previous placement of a
ES. The risk of stopping antiplatelet therapy should be
eighed against the benefit of lowering the risk of bleeding
mplications from the planned surgery. If thienopyridines
ust be discontinued before major surgery, aspirin should be
ntinued if at all possible and the thienopyridine restarted as
on as possible. There is no evidence that warfarin, anti-
rombotics, or glycoprotein IIb/IIIa agents reduce the risk of prent thrombosis after discontinuation of oral antiplatelet
ents (159).
A recent publication studied the safety of short-term
scontinuation of antiplatelet therapy in patients with DES
60). A total of 161 cases of late (30 days to 1 year) or very
te (1 year) stent thromboses were identified from the
terature; 19 cases occurred in patients who were taking dual
tiplatelet agents (aspirin and thienopyridine). Median time
stent thrombosis was 7 days in patients who stopped both
ents or had previously stopped the thienopyridine and
bsequently stopped aspirin. Median time to stent thrombo-
s was 122 days in patients who stopped thienopyridine but
ere maintained on aspirin. The authors concluded that if
pirin therapy is maintained, short-term discontinuation of
ienopyridine may be relatively safe. The authors present a
tential management strategy for patients who must undergo
ncardiac surgery but also have an elevated bleeding risk.
ccording to this strategy, elective noncardiac surgery should
eally be delayed until 1 year after DES placement. If a
ble 8. Recommendations from the 2007 AHA/ACC/SCAI/
CS/ADA Science Advisory on the “Prevention of Premature
iscontinuation of Dual Antiplatelet Therapy in Patients With
ronary Artery Stents” (159)
Before implantation of a stent, the physician should discuss the need
for dual antiplatelet therapy. In patients not expected to comply with
12 mo of thienopyridine therapy, whether for economic or other
reasons, strong consideration should be given to avoiding a DES.
In patients who are undergoing preparation for PCI and are likely to
require invasive or surgical procedures within the next 12 mo,
consideration should be given to implantation of a BMS or
performance of balloon angioplasty with provisional stent
implantation instead of the routine use of a DES.
A greater effort by healthcare professionals must be made before
patient discharge to ensure patients are properly and thoroughly
educated about the reasons they are prescribed thienopyridines and
the significant risks associated with prematurely discontinuing such
therapy.
Patients should be specifically instructed before hospital discharge to
contact their treating cardiologist before stopping any antiplatelet
therapy, even if instructed to stop such therapy by another
healthcare provider.
Healthcare providers who perform invasive or surgical procedures
and are concerned about periprocedural and postprocedural bleeding
must be made aware of the potentially catastrophic risks of
premature discontinuation of thienopyridine therapy. Such
professionals who perform these procedures should contact the
patient’s cardiologist if issues regarding the patient’s antiplatelet
therapy are unclear to discuss optimal patient management strategy.
Elective procedures for which there is significant risk of perioperative
or postoperative bleeding should be deferred until patients have
completed an appropriate course of thienopyridine therapy (12 mo
after DES implantation if they are not at high risk of bleeding and a
minimum of 1 mo for BMS implantation).
For patients treated with DES who are to undergo subsequent
procedures that mandate discontinuation of thienopyridine therapy,
aspirin should be continued if at all possible and the thienopyridine
restarted as soon as possible after the procedure because of
concerns about late stent thrombosis.
BMS indicates bare-metal stent; DES, drug-eluting stent; and PCI, percuta-
ous coronary intervention.ocedure cannot be delayed, it is optimal to continue both
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ssible. If continuation of both antiplatelet agents is not
ssible, the authors suggest holding the thienopyridine for 5
ys, performing the procedure, and then restarting the
ienopyridine on day 6 with maintenance of low-dose aspirin
roughout the perioperative period. If the patient is deemed to
at such a high risk of bleeding that both aspirin and
ienopyridine need to be stopped, the antiplatelet agents should
stopped no sooner than 5 days before the surgery and should
restarted as soon as possible after the surgery, certainly
ithin 5 days of the procedure. The latter strategy should be
ed only in cases when bleeding risk outweighs the risk of
ent thrombosis.
ecommendations for PCI and
uration of Thienopyridine Therapy
efore Kidney Transplantation
he following recommendations regarding PCI, type of stent,
d timing of surgery are consistent with the “ACC/AHA
07 Guidelines on Perioperative Cardiovascular Evaluation
d Care for Noncardiac Surgery” (7). These recommenda-
ons assume that the transplantation surgeon will not perform
elective kidney transplantation while the patient is on dual
tiplatelet therapy (aspirin plus thienopyridine), in which
se the decision making is similar to that for any other
ncardiac surgery that has excessive bleeding risk (see
commendation below for details). Because some centers
nsider the bleeding risk of kidney transplantation to be low
d thus will operate while patients continue taking dual
tiplatelet therapy, it seems reasonable (until further data
come available) for these centers to have the optimal stent
lection determined by the cardiologist in accordance with
andard PCI guidelines (140,141b). In these cases, timing
ansplantation surgery can then be determined less by the
esence of a stent/dual antiplatelet therapy and more by the
inical context of stent placement (i.e., after MI) and other
sues typically addressed by the transplantation team.
ecommendations
In patients in whom coronary revascularization with
PCI is appropriate for mitigation of cardiac symptoms
and who need transplantation surgery in the subse-
quent 12 months, a strategy of balloon angioplasty or
BMS placement followed by 4 to 12 weeks of dual
antiplatelet therapy is probably indicated (Class IIa;
Level of Evidence B).
In patients who have received DES and who must
undergo urgent surgical procedures that mandate the
discontinuation of thienopyridine therapy, it is reason-
able to continue aspirin if at all possible and to restart
the thienopyridine as soon as possible (Class IIa; Level
of Evidence C).
In cases when urgent surgery must be performed in
patients taking aspirin and thienopyridines after cor-
onary stent placement and who are at high risk for
bleeding complications, a strategy of stopping the
thienopyridine 5 days before surgery and continuing
aspirin perioperatively may be reasonable. The thien- anopyridine should be restarted as soon as possible
postoperatively (Class IIb; Level of Evidence B).
It may be reasonable to perform kidney transplanta-
tion surgery without interruption of clopidogrel ther-
apy if the risk of bleeding is low (Class IIb; Level of
Evidence C).
Transplantation surgery within 3 months of BMS
placement and within 12 months of DES placement is
not recommended, particularly if the anticipated time
of poststent dual antiplatelet therapy will be shortened
(Class III; Level of Evidence B).
Transplantation surgery is not recommended within 4
weeks of coronary revascularization with balloon an-
gioplasty (Class III; Level of Evidence B).
reoperative Cardiovascular
isk Factor Modification in
enal Transplantation Candidates
lood Pressure Management in
idney Transplantation Candidates
he optimal management of blood pressure for dialysis
tients remains an enigma. The NKF/KDOQI “Clinical
ractice Guidelines on Hypertension and Antihypertensive
gents in Chronic Kidney Disease” recommend predialysis
d postdialysis blood pressure goals of 140/90 and
130/80 mm Hg, respectively, in large part on the basis of
inical trials in patients with CKD and 1 prospective obser-
tional trial in a dialysis population in whom blood pressure
140/90 mm Hg minimized the occurrence of cardiovascular
mplications and death (161).
Diagnosing and treating hypertension in patients on hemo-
alysis remains controversial despite the NKF/KDOQI and
idney Disease: Improving Global Outcomes (KDIGO)
inion-based guidelines (161,162). There is no evidence
om randomized controlled trials that lowering blood pres-
re in dialysis patients reduces subsequent MACEs. Some
hort studies suggest that when the NKF/KDOQI targets are
hieved, patients on hemodialysis have more frequent epi-
des of intradialytic hypotension (163). In addition, there is
ly a weak correlation between predialysis and postdialysis
ood pressure measurements and interdialytic 44-hour am-
latory blood pressure (164,165). More recently, clinical
udies have demonstrated that interdialytic home blood
essure measurements are more reflective of interdialytic
-hour ambulatory blood pressure monitoring (166). More-
er, home and 44-hour ambulatory blood pressure monitor-
g are better determinants of all-cause mortality in patients
hemodialysis compared with predialysis or postdialysis
cordings (167,168). These data in dialysis patients are
nsistent with observations in nondialyzed patients with
KD. In patients with CKD, home blood pressure recordings
e a better predictor of risk for ESRD and all-cause mortality
mpared with office-based readings (169). Although several
servational cohort studies indicate that hypertension in
alysis patients is associated with increased mortality risk,
her studies have reported associations between low systolic
d diastolic blood pressures and increased mortality (170).
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July 31, 2012:434–80 Cardiac Disease Evaluation and Management Among Transplantation Candidateslthough this paradoxical observation may reflect a greater
evalence of systolic and diastolic dysfunction in patients on
alysis, it raises important questions about optimal blood
essure goals. A recent meta-analysis of randomized con-
olled trials of blood pressure–lowering treatment in dialysis
tients who achieved average systolic and diastolic reduc-
ons of 4.5 and 2.3 mm Hg, respectively, found that therapy
as associated with lower risks of cardiovascular events (RR,
71; 95% CI, 0.55 to 0.92), all-cause mortality (RR, 0.80;
% CI, 0.66 to 0.96), and cardiovascular mortality (RR,
71; 95% CI, 0.50 to 0.99) compared with control regimens
71). Home blood pressure recordings during the interdialytic
riod may be the optimal measure of blood pressure in dialysis
tients. Whether a blood pressure goal 130/80 mm Hg is
timal in this regard requires examination in future
inical trials.
There is also limited information on optimal approaches
r lowering blood pressure in patients on hemodialysis.
ecent clinical studies have demonstrated probing of dry weight
a progressive reduction in volume of patients on hemodialysis
a simple and efficacious strategy to improve blood pressure
ntrol (172). The study reported ultrafiltration-attributable
anges in systolic and diastolic blood pressure of 6.9 and
3.1 mm Hg, respectively, at 8 weeks (172). In addition,
any patients still require antihypertensive medications even
appropriate dry weight is attained. Often, drugs that block
e renin-angiotensin system are recommended as first-line
ents in patients on hemodialysis for lowering blood pres-
re. This recommendation is based in part on their tolera-
lity and extrapolation of evidence indicating benefit for
ducing MACEs in patients with earlier stages of CKD
73,174). Only 1 prospective randomized controlled trial
mpared an angiotensin-converting enzyme inhibitor, fosi-
pril, with placebo in patients on hemodialysis (175). In the
osinopril and Dialysis Trial, 400 patients on hemodialysis
50 years of age were randomized to fosinopril 20 mg/d
rsus placebo. After 4 years of follow-up, there was no
erall difference in the incidence of cardiovascular death or
tal and nonfatal cardiovascular events between the treat-
ent and control groups. However, it is quite likely that this
ial was underpowered and thus unable to answer the study
estion. Another small randomized trial of an angiotensin
ceptor blocker (candesartan) demonstrated a nearly 3-fold
duction in cardiovascular events compared with placebo
76). However, this small study needs to be replicated,
eferably with a much larger sample.
None of the available studies have evaluated blood pres-
re medications in dialysis patients on the basis of the
esence or absence of diabetes mellitus. Consequently, there
insufficient information to suggest that hypertension in
alysis patients with diabetes mellitus needs to be treated any
fferently than hypertension in dialysis patients without
abetes mellitus. In addition, no studies of antihypertensive
edications have been performed selectively in patients on
ritoneal dialysis. However, epidemiological data indicate
at the rate of cardiac arrest is 50% higher for patients on
modialysis compared with patients on peritoneal dialysis
ithin 3 months after dialysis initiation, whereas the rates are
milar 2 years after initiation and somewhat higher in aptients on peritoneal dialysis beyond 3 years after initiation
77). There is also intriguing information that long-duration
otidian dialysis is more effective for blood pressure control
d reducing left ventricular mass compared with traditional
rice-weekly hemodialysis (178).
More information is available on the treatment of blood
essure in predialysis patients with CKD. The NKF/KDOQI
linical Practice Guidelines on Hypertension and Antihy-
rtensive Agents in Chronic Kidney Disease” suggest that a
ood pressure goal below 130/80 mm Hg is appropriate in all
pes of CKD (161). They also recommend the use of drugs
at block the renin-angiotensin system in patients with CKD,
ith or without diabetes mellitus, who have a spot urine total
otein-to-creatinine ratio 200 mg/g regardless of blood
essure. The guidelines recommend moderate to high doses
these drugs because large clinical trials indicate that
timal blood pressure control and renin-angiotensin system
ockade with moderate to high doses of either angiotensin-
nverting enzyme inhibitors or angiotensin receptor block-
s may slow the progression of proteinuric kidney disease.
he NKF/KDOQI guidelines also suggest the use of other
edications to reduce cardiovascular disease risk and to
hieve blood pressure goals, in concert with the “Seventh
eport of the Joint National Committee on Prevention,
etection, Evaluation, and Treatment of High Blood Pres-
re” recommendations (180). Thus, most patients with CKD
ill require a diuretic, preferably a thiazide-type diuretic for
tients with CKD stages 1 to 3. Loop diuretics are generally
cessary in patients with CKD stages 4 and 5. Other medica-
ns such as beta-blockers and calcium channel blockers can be
ded as necessary to achieve the target blood pressure.
There is evidence that beta-blockers may be an effective
erapeutic strategy in patients on hemodialysis with LVEF
35%. Cice et al. (98) randomized 114 patients with dilated
rdiomyopathy who were on dialysis to carvedilol 25 mg
ice daily or placebo for a period of 2 years. The investi-
tors reported that carvedilol treatment reduced the risk of
rdiovascular mortality (RR, 0.32), all-cause death (RR,
51), and hospitalizations (RR, 0.44) (98).
Given the paucity of data on hard cardiovascular endpoints, there
insufficient evidence to support recommendations for 1 class of
tihypertensive agents over another in dialysis patients.
Individualized decisions on how to reach a desirable blood
essure for an individual patient need to be based on volume
sessment and the presence or absence of autonomic
sufficiency. Volume assessment is important not only in
tients on dialysis, so that an appropriate dry weight can
chosen, but also in patients with CKD, so that diuretics
n be used judiciously. Autonomic insufficiency may
mit the ability to adjust dry weight and to use medications
at clinicians may believe are necessary for cardioprotec-
on such as beta-blockers or renin-angiotensin system
ockers. No studies have been done to test the hypothesis
at dialysis patients may have less cardiovascular risk if
eir dry weight is raised to allow the use of a beta-blocker
renin-angiotensin system blocker. Consequently, ther-y should be individualized.
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idney Transplantation Candidates
he optimal use of lipid-lowering therapy in patients on
alysis is also controversial. Understanding the role of
polipemic therapy in patients on dialysis has been compli-
ted by conflicting data on the overall relationship of
slipidemia with clinical outcomes in this population. Sev-
al observational studies reported associations of lower total
rum cholesterol levels in patients on dialysis with increased
sk of cardiovascular and all-cause mortality (181–183),
though others found mortality relationships parallel to that
the general population (184). A recent prospective cohort
udy of 823 patients receiving incident dialysis clarified the
le of confounding in the apparent “reverse epidemiology”
lipid levels and ESRD mortality (185). Higher total
olesterol levels were associated with reduced risk of
l-cause death overall and in the subgroup with malnutrition
d/or inflammation (defined as serum albumin levels 3.6
g/dL, C-reactive protein10 mg/L, or elevated interleukin-6).
contrast, each 40-mg/dL increment in baseline cholesterol
as associated with increased risk of both all-cause (HR, 1.32;
% CI, 1.07 to 1.63) and cardiovascular (HR, 1.41; 95% CI,
04 to 1.89) death among the participants without inflamma-
n/malnutrition. These findings support mediation of the ap-
rent survival advantage of hypercholesterolemia in ESRD by
olesterol-lowering effects of malnutrition and/or inflammation
ther than by true protective effects of high cholesterol levels.
Data on the impact of statin therapy on cardiovascular
tcomes and mortality in large cohorts of dialysis patients
gan with observational studies. A large observational study
prospective outcomes among patients receiving incident
ritoneal dialysis and hemodialysis enrolled in the USRDS
MMS (Dialysis Morbidity and Mortality Study) Wave 2
hort suggested significant, 30% relative reductions in
rdiovascular and total mortality among statin users com-
red with nonusers (186). Similar effect sizes were reported
ith more extended follow-up of the subcohort receiving
ritoneal dialysis (187). In an analysis of prospectively
llected data for prevalent hemodialysis patients in the
nited States, Europe, and Japan participating in DOPPS
ialysis Outcomes and Practice Patterns Study), statin pre-
ription was associated with a 31% lower relative risk of
ath and 23% lower relative risk of cardiac death compared
ith no statin prescriptions (188). Notably, only 11.8% of this
hort received statin prescriptions. Importantly, none of
ese observational studies analyzed the duration of statin
eatment before enrollment. Moreover, observational find-
gs are limited by the potential for selection bias and residual
nfounding. Beginning in the late 1990s, a number of
udies enrolled small samples of dialysis patients in clinical
ials comparing statin therapy and placebo, but most were of
ort duration and examined lipid levels or other surrogate
easures as primary outcomes (Table 9) (189–196). These
udies documented effective lipid lowering by statins at low
moderate doses without significantly increased risks of
verse side effects. On the basis of the available body of
idence in patients on dialysis and extrapolation from
neral population trials, the 2003 NKF/KDOQI “Clinical thractice Guidelines for Managing Dyslipidemias in Chronic
idney Disease” recommended treatment to reduce low-
nsity lipoprotein (LDL) cholesterol to 100 mg/dL in
ults with stage 5 (end-stage) CKD (197). These guidelines
ralleled recommendations of the Adult Treatment Panel
TP) for higher-risk members of the general population
ithout established coronary heart disease (198).
Three randomized trials of statin therapy in dialysis pa-
ents using clinical endpoints have since been published
able 9). Stegmayr et al. (199) randomly assigned 143
tients with CKD, including 110 on dialysis, to atorvastatin
mg daily or placebo. After a mean observation time of 33
onths in the dialyzed subgroup, there was no significant
fference in the risk of the primary outcome of all-cause
ath, MI, or coronary revascularization according to treat-
ent assignment (OR, 1.01; 95% CI, 0.65 to 1.55). The 4D
tudy (Deutsche Diabetes Dialyze Studie), randomized 1,255
tients on hemodialysis with type 2 diabetes mellitus to
orvastatin 20 mg daily or placebo (199a). Participants had
en dialysis dependent for an average of 8 months at
rollment. Median LDL cholesterol levels declined by 42%
72 mg/dL after 4 weeks in the statin group compared with
1.3% reduction with placebo. Despite effective lipid lower-
g, atorvastatin did not significantly affect the composite
imary endpoint of cardiac death, MI, or stroke (RR, 0.92;
% CI, 0.77 to 1.10) after a median follow-up of 4 years.
econdary endpoint analysis demonstrated nominally signif-
ant associations of atorvastatin with a higher frequency of
tal stroke (27 versus 13 events; RR, 2.03; 95% CI, 1.05 to
93; p0.04) but protection against any cardiac event (RR,
82; 95% CI, 0.68 to 0.99; p0.03). AURORA (Assessment
Survival and Cardiovascular Outcomes), which did not
strict enrollment according to ESRD pathogenesis, random-
ed 2,776 patients 50 to 80 years of age on chronic
modialysis for at least 3 months to rosuvastatin 10 mg daily
placebo (200). Mean LDL cholesterol levels declined by
% after 12 weeks in the statin group to 60 mg/dL
mpared with a 1.9% reduction with placebo. There was no
fference in the incidence of the primary endpoint of cardio-
scular death, nonfatal MI, or stroke (RR, 0.96; 95% CI,
84 to 1.11) in the statin compared with placebo arms, nor
ere there any differences in the risk of individual compo-
nts of the primary endpoint. The lack of an effect of
suvastatin therapy on the primary endpoint was consistent
prespecified subgroups, including patients with diabetes
ellitus and preexisting cardiovascular disease.
The findings of the 4D Study and AURORA contrast with
eatment-related benefits found in CARDS (Collaborative Ator-
statin Diabetes Study), a trial conducted in 2,838 patients with
pe 2 with diabetes mellitus without significant renal impair-
ent at enrollment (serum creatinine levels1.7 mg/dL) (201).
fter a median follow-up of 3.9 years in CARDS, atorvastatin
mg produced a 37% relative reduction in MACEs and a 27%
duction in all-cause mortality compared with placebo (201).
ardiac death in patients on dialysis is often sudden, resulting
om arrhythmia or heart failure, and these competing risks have
esented challenges for powering trials to detect benefits on
herosclerotic events in this population. One possibility for
ese discrepancies is that the increased risk for sudden death in
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rial Authors, Year
Sample Size,
Dialysis Modality
Statin, mg/d, and
Comparison
Enrollment in
Relation to
ESRD Onset,
mo
Trial
Duration,
mo Primary Outcome Results
bson et al. (189),
97
107 HD or PD SIMV 10 versus
placebo (factorial with
enalapril versus
placebo)
6 Lipid levels at 6 mo Significantly lower TCHOL
(13%) and LDL (17%) at
6 mo with SIMV versus
placebo
ang et al. (190),
02
62 HD SIMV 20 versus no
drug
21 (median) 2 Longitudinal change in
lipid and inflammatory
marker levels
Significant longitudinal
reductions in TCHOL
(29%), LDL (41%), TG
(17%) and hs-CRP only
with SIMV
rris et al. (191),
02
177 PD ATORV 10–40 versus
placebo
3 4 Longitudinal change in
lipid levels
Significantly larger
longitudinal reductions in
TCHOL (29% versus 6%),
LDL (40% versus 9%)
and TG (14% versus
11%) and larger HDL
increase (7% versus 4%)
with ATORV versus
placebo
ltissi et al. (192),
02
22 HD, 16 PD SIMV 5–20 versus
placebo
3 6 Longitudinal change in
lipid levels
Significantly larger
longitudinal reductions in
TCHOL and LDL with
SIMV versus placebo in
both HD and PD groups
s et al. (193),
04
42 HD ATORV 10–40 versus
placebo
3 Lipid levels at 3 mo Significantly lower TCHOL
(33%) and LDL (43%) at
3 mo with ATORV versus
placebo
epeveen et al.
94), 2005
23 HD, 21 PD ATORV 40 versus
placebo (factorial with
vitamin E versus
placebo)
Unspecified 3 Longitudinal change in
nonfasting lipid levels
Significant longitudinal
reductions in TCHOL
(34%), LDL (43%), and
TG (34%) only with SIMV
igent et al.
95), 2005
34 HD, 39 PD (subset
of 448 CKD)
SIMV 20 versus
placebo (factorial with
aspirin versus placebo)
Unspecified 12 Nonfasting lipid levels
at 12 mo
Significantly lower TCHOL
(16%), LDL (20%), and
TG (38%) at 12 mo with
SIMV versus placebo
ihara et al.
96), 2002
22 HD FLUV 20 versus
placebo
6 6 Longitudinal change in
arterial stiffness
Significant longitudinal
decrease in arterial pulse
wave velocity only with
FLUV
egmayr et al.
99), 2005
97 HD, 13 PD (subset
of 143 CKD)
ATORV 10 versus
placebo
Unspecified 33 (mean) All-cause death, MI,
CABG or PCI
No outcome difference:
OR, 1.01; 95% CI, 0.65
to 1.55
anner et al.
99a), 2005
1,255 HD ATORV 20 versus
placebo
24 (mean 8) 48 (median) Cardiac death,
nonfatal MI, or stroke
No significant outcome
difference: RR, 0.92;
95% CI, 0.77 to 1.10
llstrom et al.
00), 2009
2,776 HD ROSUV 10 versus
placebo
4246
(mean)
46 (median) Cardiovascular death,
nonfatal MI, or stroke
No significant outcome
difference: RR, 0.96;
95% CI, 0.84 to 1.11
igent et al.
02), 2011
2,527 HD, 496 PD
(subset of 9,720 CKD)
SIMV 20 plus ezetimibe
10 versus placebo
Unspecified 59 (median) Nonfatal MI or
coronary death, non–
hemorrhagic stroke, or
arterial
revascularization
Significant reduction in
composite event rate with
SIMV plus ezetimibe in
the full cohort (RR 0.83;
95% CI, 0.74 to 0.94;
p0.002). No evidence
of heterogeneity of
effects among dialysis
versus non-dialysis
patients
ATORV indicates atorvastatin; CABG, coronary artery bypass grafting; CI, confidence interval; CKD, chronic kidney disease; ESRD, end-stage renal disease; FLUV, fluvastatin;
, hemodialysis; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; MI, myocardial infarction; OR, odds ratio; PCI,
rcutaneous coronary intervention; PD, peritoneal dialysis; ROSUV, rosuvastatin; RR, relative risk; SIMV, simvastatin; TCHOL, total cholesterol; and TG, triglycerides.
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Cardiac Disease Evaluation and Management Among Transplantation Candidates July 31, 2012:434–80tients on dialysis may not be mitigated by cholesterol-
wering therapy, which may be much more important for
chemic, atherosclerotic events. Thus, the 4D Study may not
ve been able to show a modest benefit on atherosclerotic
dpoints given the large numbers of patients who had arrhyth-
ic death or congestive failure. Furthermore, decisions on target
DL cholesterol goals may be limited by the fact that many
tients on dialysis have low LDL cholesterol related to malnu-
ition or concomitant inflammation.
Importantly, results from the SHARP (Study of Renal and
eart Protection) clinical trial were published in 2011 (202).
he study included 9,270 patients with CKD (defined as
rum creatinine level 1.7 mg/dL in men or serum creati-
ne level 1.5 mg/dL in women, on hemodialysis, or on
ritoneal dialysis), 40 years of age, and no prior history of
I or coronary revascularization who were randomly as-
gned to receive simvastatin 20 mg plus ezetimibe 10 mg or
acebo. The primary endpoint of MACEs was defined as a
mposite of nonfatal MI or coronary death, non–hemor-
agic stroke, or arterial revascularization (excluding dialysis
cess procedures) but, in contrast to 4D and AURORA, did
t include sudden cardiac death. After a median 4.9 years of
eatment and follow-up, average LDL cholesterol was 42
g/dL lower in the simvastatin plus ezetimibe group com-
red with placebo group by intention-to-treat analysis. The
mvastatin plus ezetimibe group experienced a 17% reduc-
on in the relative risk of MACEs (RR 0.83; 95% CI, 0.74 to
94; p0.002). Non-significantly fewer patients allocated to
mvastatin plus ezetimibe had a non-fatal MI or died from
ronary heart disease (RR 0.92, 95% CI 0.76 to 1.11;
0.37), and there were significant reductions in non–
morrhagic stroke (RR 0.75, 95% CI 0.60 to 0.94; p0.01)
d arterial revascularization procedures (RR 0.79, 95% CI
68 to 0.93; p0.0036). After weighting for subgroup-
ecific reductions in LDL cholesterol in a planned compar-
on, there was no heterogeneity of effects among dialysis-
pendent patients (one third of the total) compared with
tients not on dialysis, but the study was not powered to
sess outcomes among the dialysis group alone. Further,
cause approximately one third of the patients who were not
dialysis at baseline began dialysis during the trial, the
fects of simvastatin plus ezetimibe in the dialysis subgroup
e reinforced by the consistent results in the non-dialysis
bgroup. The excess risk of myopathy was 2 per 10,000
tients per year of treatment with simvastatin plus ezetimibe
mpared with placebo. There was no evidence of excess
sks of hepatitis, gallstones, or cancer, and there was no
gnificant excess of death from any non-vascular cause.
A meta-analysis and meta-regression of randomized con-
olled trials of statins in CKD patients (broadly defined as
edialysis, dialysis, and transplantation populations) included
e 4D Study but not AURORA or SHARP (204). In pooling
fects across 43 trials, the authors detected a 19% relative
duction in fatal cardiovascular events with statin use (RR,
81; 95% CI, 0.73 to 0.90), an effect that approximates the
nefits of statin treatment in the general population. Statistical
sessment for heterogeneity supported consistency of the car-
ovascular benefit across the predialysis, dialysis, and trans-
antation samples, although power for detecting heterogeneity (2as limited. Statins were associated with a trend toward lower
erall mortality, but this effect was not significant (RR, 0.92;
% CI, 0.82 to 1.03; p0.13). The authors concluded that the
ndings “provide support for the widespread use of statins for
e prevention of cardiovascular disease in people with chronic
dney disease who are at high cardiovascular risk . . ., but that
e effects of treatment in people at lower absolute risk and the
fects on total mortality remain to be defined.” Meta-analysis of
e dialysis populations in SHARP, 4D, and AURORA exam-
ing the combined effects of treatment on the “atherosclerotic”
dpoint as it was defined in SHARP will further refine the
idence of the impact of statins on vascular risk in dialysis-
pendent patients.
The reported trials using low- to moderate-dose statins in
tients on dialysis support safety and tolerability at this dose
nge in the dialyzed population. Frequencies of liver function
st abnormalities, creatinine phosphokinase elevations, and
rticipant withdrawals were similar with statins compared with
acebo or control (191–193,195,199,199a,200). The AURORA
udy observed 3 cases of rhabdomyolysis (0.2%) in patients
ndomized to rosuvastatin and 2 cases in the placebo group
.1%) (200). Although there were more fatal stroke events in
e atorvastatin group in the 4D Study (199a), this nominally
gnificant finding is not consistent with major trials such as
ARDS and the Heart Protection Study, which demonstrated
% to 48% relative reductions in stroke risk with statins in
gh-risk general population samples (201,205). There was no
gnificant difference in nonfatal stroke with rosuvastatin com-
red with placebo in AURORA (p0.42) (200). Simvastatin
us ezetimibe was associated with a significant 25% relative
duction in non–hemorrhagic stroke (p0.01) in the full
HARP cohort (202).
ecommendation
It may be reasonable to administer statins to kidney
transplantation candidates to reduce the risk of vascu-
lar disease events (Class IIb; Level of Evidence B).
erioperative Medical Management
f Cardiovascular Risk Before
idney Transplantation
here are several important perioperative management strat-
ies to consider for reducing the risk for cardiovascular
ents in patients with CKD and ESRD without known CAD.
he most important include management considerations for
ood pressure, glycemic control, and antiplatelet therapy.
portant questions include whether patients should take
me or all of their antihypertensive medication the day of
rgery. Often, especially with deceased donor transplanta-
on, the timing of the surgery precludes advanced planning
r medications. In addition, one has to consider interactions
ith other medications during surgery, especially analgesics.
ata indicate that beta-blockers improve cardiovascular out-
mes in CKD patients having noncardiac surgery. In a
trospective study of 2,000 vascular surgery patients, half of
hom had abdominal aortic aneurysm repairs, Welten et al
06) reported that the benefit of judiciously titrated beta-
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July 31, 2012:434–80 Cardiac Disease Evaluation and Management Among Transplantation Candidatesockers in reducing cardiovascular events increased with
clining creatinine clearance. The overall benefit was first
ted when estimated creatinine clearance by the Cockcroft
d Gault formula was 60 mL/min and most evident when
timated creatinine clearance was 30 mL/min, suggesting
at CKD patients may benefit from perioperative use of
ta-blockers. Whether CKD patients require long-term beta-
ocker treatment in the absence of clinically evident cardio-
scular disease is unknown. Certainly, patients receiving
ta-blockers as long-term therapy before surgery should be
ntinued on beta-blockers perioperatively and postopera-
vely because the risk for rebound blood pressure elevations
n be substantial and may precipitate coronary ischemia. In
dition, medications such as clonidine, if given before
ansplantation, should be continued perioperatively and post-
eratively to avoid rebound blood pressure elevations.
eta-blockers can be given intravenously and clonidine
anscutaneously in cases of postoperative ileus.
Perioperative medical therapy can be useful for reducing
rioperative cardiovascular complications in patients with es-
blished CAD. Mangano et al. (207) administered atenolol or
acebo beginning the morning of surgery and continuing for 7
ys postoperatively to a cohort of 200 patients with known
ronary disease or CAD risk factors undergoing high-risk
ncardiac surgery. There was a marked reduction in the
cidence of perioperative myocardial ischemia and an improve-
ent in survival at 6 months in the atenolol group, with benefit
rsisting for at least 2 years. The authors speculated that the
wer incidence of myocardial ischemia was the result of
ta-blockers protecting against plaque destabilization, with a
sultant reduction in subsequent MI or death. Poldermans et al.
08) studied the perioperative use of bisoprolol versus routine
re in elective major vascular surgery in the DECREASE trial.
isoprolol was started at least 7 days preoperatively, titrated to
hieve a resting heart rate 60 bpm, and continued postoper-
ively for 30 days. Of note, the study was confined to patients
ith at least 1 clinical marker of cardiac risk (prior MI, diabetes
ellitus, angina pectoris, heart failure, age 70 years, or poor
nctional status) and evidence of inducible myocardial ischemia
a preoperative DSE. Patients with extensive regional wall
normalities (large zones of myocardial ischemia) were ex-
uded. Bisoprolol, when titrated carefully, reduced periopera-
e MI or cardiac death by nearly 80% in this high-risk population.
In contrast, several recent studies have demonstrated that
ta-blockers may not be effective if heart rate is not well
ntrolled or when given unselectively to lower-risk patients
09–211). The POISE (Perioperative Ischemic Evaluation)
ial reported on 8,351 high-risk, beta-blocker–naïve patients
ndomized to high-dose continuous-release metoprolol the
ght before and the morning of surgery versus placebo (212).
reatment was associated with a significant reduction of the
imary outcome of cardiovascular events and with a 30%
duction in MI risk, but was also associated with significantly
creased risk of 30-day all-cause mortality and stroke. POISE
s been criticized because the use of high-dose beta-blocker
erapy the night before and morning of surgery probably led to
gher rates of hypotension, stroke, and death.
The DECREASE-IV trial enrolled patients who were 40
ars of age, were scheduled for elective noncardiac surgery,d had an estimated risk of MI or cardiovascular death of
1% (212a). Participants were randomized according to an
en-label, factorial design to 1) beta-blocker therapy (biso-
olol), 2) statin (fluvastatin), 3) a combination of beta-blockers
d statins (bisoprolol and fluvastatin 80 XL), or 4) neither
ta-blockers nor statins (control group). The starting dose of
soprolol was 2.5 mg orally per day if resting heart rate was
50 bpm and increased incrementally to a maximum dose of 10
g. Patients randomized to bisoprolol (n533) had a lower
cidence of perioperative cardiac death and nonfatal MI than
ose randomized to control (2.1% versus 6.0% events; HR,
34; 95% CI, 0.17 to 0.67). Ischemic stroke occurred in 0.7% of
tients (n7), of whom 4 (0.8%) were randomized to biso-
olol and 3 (0.6%) to bisoprolol-control (p0.68).
The “ACC/AHA 2007 Guidelines on Perioperative Cardio-
scular Evaluation and Care for Noncardiac Surgery” (7)
d the “2009 ACCF/AHA Focused Update on Perioperative
eta Blockade” (213) have advocated that perioperative
ta-blockade is a Class I indication (should be provided) for
tients previously on beta-blockers for indications such as
gina, symptomatic arrhythmias, and hypertension. Beta-
ockers are recommended for those with a positive stress test
dergoing major vascular surgery, although short-term ad-
inistration without titration may be associated with harm.
he short-term administration of these agents in the periop-
ative period is being rereviewed in light of the POISE
sults. The “2009 ACCF/AHA Focused Update on Periop-
ative Beta Blockade Incorporated into the ACC/AHA 2007
uidelines on Perioperative Cardiovascular Evaluation and
are for Noncardiac Surgery” focused predominantly on the
ophylactic use of beta-blockers perioperatively to minimize
rdiac risk (213). The DECREASE-IV trial demonstrated a
fe and effective manner of providing these agents (212a).
he cardiovascular evaluation process in patients undergoing
lid-organ transplantation presents an opportunity to initiate
is therapy in patients with Class I recommendations for
ta-blockers independently of surgery and to perform appro-
iate titration before the perioperative period. The potential
nefits of continuing perioperative beta-blockers could then
realized with a low risk of detrimental side effects.
ecommendations
Among patients already taking beta-adrenergic blockers
before renal transplantation, continuing the medication
perioperatively and postoperatively is recommended to
prevent rebound hypertension and tachycardia (Class I;
Level of Evidence A).
Among patients being considered for renal transplan-
tation with clinical markers of cardiac risk (diabetes
mellitus, prior known coronary heart disease, prior
heart failure, extracardiac atherosclerosis) and those
with unequivocal myocardial ischemia on preoperative
stress testing, it is reasonable to initiate beta-blockers
preoperatively and to continue them postoperatively
provided that dose titration is done carefully to avoid
bradycardia and hypotension (Class IIa; Level of Evi-
dence C).
3.
4.
ev
pe
st
bl
co
er
af
w
in
id
al
go
be
an
si
ca
av
an
su
op
pr
ad
th
st
re
fu
ie
fu
re
an
fo
th
ti
us
gr
an
th
th
fu
R
1.
ge
th
va
tr
pa
(H
as
or
M
re
m
by
m
de
m
(2
in
ba
in
so
pa
pr
ri
C
an
R
1.
(2
re
w
si
ca
(2
av
pl
si
L
fo
ti
gu
ta
R
1.
2.
462 Lentine et al. JACC Vol. 60, No. 5, 2012
Cardiac Disease Evaluation and Management Among Transplantation Candidates July 31, 2012:434–80Perioperative initiation of beta-blockers in beta-block-
er–naïve patients may be considered in kidney trans-
plantation candidates with established coronary heart
disease or 2 or more cardiovascular risk markers to
protect against perioperative cardiovascular events if
dosing is titrated and monitored (Class IIb; Level of
Evidence C).
Initiating beta-blocker therapy in beta-blocker–naïve
patients the night before and/or the morning of non-
cardiac surgery is not recommended (Class III; Level
of Evidence A).
Other than beta-blocker treatment and clonidine, there is no
idence to support the continued use of any specific antihy-
rtensive therapy. Calcium channel blockers may be re-
arted as the blood pressure rises postoperatively. Drugs that
ock the renin-angiotensin system such as angiotensin-
nverting enzyme inhibitors or angiotensin receptor block-
s are usually withheld within the first few days to weeks
ter transplantation to avoid functional changes in GFR,
hich could delay recovery from ischemia and reperfusion
jury and thus possibly confuse clinical management. An
eal postoperative blood pressure goal should be individu-
ized on the basis of the patient’s presurgical blood pressure
als. Often in the perioperative period, blood pressure is low
cause of the effects of anesthesia and concomitant use of
algesic medications. Consequently, an individualized deci-
on to progressively add medications should be done on a
se-by-case and day-by-day basis. Hypotension should be
oided because it may worsen ischemic injury to the kidney
d possibly precipitate graft thrombosis. Patients with pre-
rgical tolerance to opiate analgesics may experience post-
erative rebound in blood pressure if inadequate opiates are
ovided to relieve wound discomfort. In such patients,
justing opiate doses for postoperative hypertension rather
an adding blood pressure medications may be the best
rategy.
There is no evidence to indicate that dopamine improves
nal perfusion or diminishes the risk of delayed graft
nction after transplantation when administered to the recip-
nt (214), although data indicate some benefit for kidney
nction if given to the deceased donor (215). In some
cipients, dopamine may increase heart rate, blood pressure,
d myocardial workload, effects that may increase the risk
r an ischemic event. Because no data indicate benefit from
e use of dopamine perioperatively, it should not be rou-
nely used. Likewise, there is no evidence that perioperative
e of calcium channel blockers reduces the risk of delayed
aft function. Again, the use of these drugs perioperatively
d postoperatively needs to be individualized on the basis of
e need for control of blood pressure, not unproven hypo-
etical opportunities for improving postimplantation graft
nction.
ecommendation
Administration of dopamine to the kidney transplant
recipient is not beneficial for renal allograft function,
and administration may be harmful (Class III; Level of
Evidence C).Decisions on antiplatelet therapy perioperatively cannot be
neralized. No randomized controlled trials have evaluated
e efficacy of aspirin for the primary prevention of cardio-
scular disease in patients on dialysis, although 1 controlled
ial found a reduced risk of MI with aspirin therapy in CKD
tients (216). A recent secondary analysis of the HOT
ypertension Optimal Treatment) trial, which randomly
signed patients with diastolic hypertension to aspirin 75 mg
placebo, detected a 66% reduction (95% CI, 33 to 83) in
ACEs and a 49% reduction (95% CI, 6 to 73) in mortality,
spectively, among the subgroup with baseline eGFR 45
L/min/1.73 m2 (217). This potential benefit must be offset
the risk of gastrointestinal bleeding, albeit minor in the
ajority of cases. On the other hand, observational studies
monstrate that aspirin therapy is associated with reduced
ortality in patients with CKD who have had a previous MI
18,219). Decisions on continuing antiplatelet therapy dur-
g surgery and perioperatively need to be individualized
sed on indication and bleeding risk because there are
sufficient data to guide management in this regard. Although
me programs routinely continue low-dose aspirin therapy in
tients with CKD and ESRD perioperatively, many surgeons
efer not to continue clopidogrel given concern about increased
sk of bleeding. Please see “Antiplatelet Therapy in the
ontext of Recent PCI” section above for a discussion of
tiplatelet therapy in the context of recent PCI.
ecommendation
It is reasonable to continue aspirin indefinitely after
renal transplantation in patients with known CAD,
following the ACC/AHA guidelines for secondary pre-
vention for patients with coronary artery disease (Class
IIa; Level of Evidence B).
With respect to perioperative use of statins, Durazzo et al.
20) performed a randomized trial among 200 patients
ceiving vascular surgery (without ESRD) in whom statins
ere started an average of 30 days before surgery. A
gnificant reduction in perioperative cardiovascular compli-
tions was demonstrated with this protocol. Schouten et al.
21) performed a randomized trial of fluvastatin started an
erage of 30 days before noncardiac surgery compared with
acebo in 497 statin-naïve, high-risk patients and found a
gnificant reduction in perioperative MI and cardiac death.
e Manach et al. (222) demonstrated that statin withdrawal
r 4 days before vascular surgery was associated with 2.9
mes the odds of cardiac morbidity. Therefore, the recent
idelines advocate continuing statin therapy in patients
king statins as a Class I recommendation.
ecommendations
For patients undergoing renal transplantation who are
taking statin therapy, it is recommended that statin
treatment be continued perioperatively and postoper-
atively (Class I; Level of Evidence B).
For patients undergoing renal transplantation in
whom preoperative evaluation established unequivocal
evidence of atherosclerosis, it is reasonable to initiate
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July 31, 2012:434–80 Cardiac Disease Evaluation and Management Among Transplantation Candidateslow- to moderate-dose statin therapy preoperatively
and to continue treatment postoperatively (Class IIa;
Level of Evidence B).
Glycemic control holds promise for reducing cardiovascu-
r mortality in the perioperative period for patients with
abetes mellitus receiving kidney transplantation. A meta-
alysis of 35 randomized controlled trials with mortality
ta on critically ill hospitalized adult patients treated with
sulin reported a 15% reduction in the relative risk of
ort-term mortality (RR, 0.85; 95% CI, 0.75 to 0.97) with
sulin versus control therapy, including benefit among the
bgroup in the surgical intensive care unit (RR, 0.58; 95%
I, 0.22 to 0.62) (223). Similarly, a more recent systematic
view and meta-analysis suggested that perioperative insulin
fusion versus control therapy may reduce perioperative
ortality in patients undergoing any surgery, including a
arly significant benefit in patients with acute MI who did
t receive reperfusion therapy, but at the “expense” of an
creased risk of hypoglycemia (224). Meta-analysis of 5
udies (3 randomized trials and 2 cohort) comparing inten-
ve and conventional insulin in critically ill patients reported
reduction in the incidence of acute kidney injury by 38%
ith intensive therapy (RR, 0.62; 95% CI, 0.47 to 0.83)
25). These observations suggest potential benefit for inten-
ve insulin in reducing delayed graft function after transplan-
tion. However, the recently published NICE-SUGAR (Nor-
oglycaemia in Intensive Care Evaluation and Survival
sing Glucose Algorithm Regulation) study, a large random-
ed trial of intensive versus conventional insulin therapy
ong 6104 adults in medical or surgical intensive care units
ho were expected to require insulin on at least 3 consecutive
ys, found higher 90-day mortality (RR, 1.14; 95% CI, 1.02
1.28) with a more intensive glucose management target of
to 108 mg/dL compared with a target of 180 mg/dL
26). Thus, although glycemic control may offer a benefit in
e perioperative setting, caution with intensive therapy is
arranted.
Many transplantation centers routinely admit incident
ansplantation patients to monitored beds for the first few
ys postoperatively. Often, this is part of the management
rategy for routine assessment of fluid management in the
rioperative period. However, no data suggest that routine
onitoring for a prespecified period of time affects the risk
r cardiovascular events.
In summary, there are limited published data on optimal
rioperative medical management of cardiovascular risks in
tients with CKD and ESRD undergoing renal transplanta-
on. Perhaps most important is an individualized approach to
anaging blood pressure to minimize fluctuations, to avoid
potension, and to progressively reinstitute safe and effec-
ve therapies that will not interact with other medications or
ter GFR. Cautious reintroduction of medications as anes-
esia and analgesia are tapered can be individualized on a
se-by-case basis.
ecommendation
The usefulness of strict control of blood glucose con-
centration during the perioperative period is uncertain vain patients with diabetes mellitus undergoing kidney
transplantation (Class IIb; Level of Evidence B).
ostoperative Medical Management
f Cardiovascular Risk After
idney Transplantation
reatment of Elevated LDL Cholesterol Levels
Kidney Transplant Recipients
o date, there are no definitive data indicating that treatment
hyperlipidemia in kidney transplant recipients improves
inical outcomes such as patient survival, allograft survival,
risk of cardiovascular events. However, there is indirect
idence of benefits with statin therapy. The Assessment of
escol in Renal Transplantation (ALERT) is the only ran-
mized controlled trial of dyslipidemia management in this
pulation that used cardiovascular disease events as the
tcome measure (227). The ALERT trial randomized 2,102
nal transplant recipients with mean total cholesterol levels
250 mg/dL to fluvastatin or placebo. After a mean
llow-up of 5.1 years, LDL levels were 32% lower in the
atin-treated compared with the placebo group (average
fference of 38 mg/dL). Statin therapy was associated with a
end toward lower incidence of the primary composite
tcome of cardiac death, nonfatal MI, or coronary interven-
ons, although the risk reduction did not reach statistical
gnificance (RR, 0.83; 95% CI, 0.64 to 1.06). In contrast, an
tension of the ALERT study in which patients were offered
uvastatin for an additional 2 years found significant long-
rm reduction in the primary composite outcome among the
iginal statin arm (228). At a mean follow-up of 7 years after
rollment, the fluvastatin-treated patients had a lower risk of
e primary cardiac composite outcome compared with the
iginal placebo group (HR, 0.79; 95% CI, 0.63 to 0.99), but
ere was no significant difference in overall mortality.
Posthoc analysis of the ALERT trial suggested signifi-
ntly lower risk of cardiac death or nonfatal MI with
uvastatin compared with placebo (RR, 0.65; 95% CI, 0.48 to
88) (229). Patients who started statin therapy earlier after
ansplantation appeared to benefit more than those who
gan treatment later (230). Compared with those who
itiated statin therapy 6 years after transplantation, those
ho began therapy between years 0 to 2 after transplantation
perienced 59% lower risk of cardiac death and nonfatal MI.
A number of smaller randomized clinical trials have
aluated associations of statin therapy with surrogate mea-
res of atherosclerotic vascular disease risk in renal allograft
cipients such as lipid profiles and measures of endothelial
nction (Table 10). Findings of these trials include average
ductions in total cholesterol of 18% to 33%, LDL choles-
rol reductions of 20% to 42%, triglyceride reductions of 0%
32%; and average high-density lipoprotein (HDL) levels
creases of 0% to 13% (195,231–235). Improvements in
atin-treated groups have been reported in ultrasonographic
easures of endothelial and vessel wall function (242,244),
rotid intimal-medial thickness (243), and renal allograft
sculopathy (241).
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Cardiac Disease Evaluation and Management Among Transplantation Candidates July 31, 2012:434–80A large, observational cohort study of 2041 consecutive,
rst-time kidney transplant recipients at 1 center in Austria in
90 to 2003 used pharmaceutical and death records to
amine survival in relation to statin use in a time-dependent
gression analysis (246). The study estimated a 36% relative
duction in adjusted mortality over up to 12 years of
llow-up in statin-treated patients (adjusted HR, 0.64; 95%
I, 0.48 to 0.86).
Notably, the ATP III and NKF/KDOQI guidelines were
blished before more recent data suggesting benefit with
ore aggressive lipid-lowering in high-risk general popula-
on samples, albeit with increased frequency of adverse
ents (247–250), and evidence that statin therapy may
duce MACEs in apparently healthy individuals without
perlipidemia but with elevated serum inflammatory mark-
s (251). However, recommendations for more aggressive
pid lowering have not been adopted by the recent KDIGO
idelines. Data on the safety and efficacy of the cholesterol-
take inhibitor ezetimibe in transplant recipients are limited
small observational studies (252–255). The 2004 NKF/
DOQI “Clinical Practice Guidelines for Managing Dyslipi-
mias in Kidney Transplant Patients” advised that ezetimibe
ould probably not be used in the transplantation population
til its safety is established (256).
Observational studies have identified HDL cholesterol 40
g/dL as an independent risk factor for coronary heart disease
en after adjustment for LDL cholesterol levels. The first line of
eatment for this pattern of dyslipidemia is therapeutic lifestyle
ange. There are no reported studies of treatment of isolated
w HDL cholesterol levels in kidney transplant recipients.
With respect to side effects of antidyslipidemic drug in
dney transplant recipients, the randomized controlled trials
statin use among renal allograft recipients have reported
me adverse event data, but ascertainment methods varied
ross studies (195,227,231–243,245). The ALERT trial cap-
red the largest sample for the longest follow-up (10,000
tient-years) and found no difference in the frequencies of
tal or types of adverse events among patients treated with
uvastatin compared with placebo, including no differences
infections, malignancies, substantial creatinine kinase ele-
tions, or rhabdomyolysis (227). Importantly, these studies
not suggest harm attributable to statin therapy started
fore or perioperatively in patients undergoing kidney trans-
antation. Limited data are available on the safety of com-
ning fibrates with statins in patients with kidney disease,
d NKF/KDOQI guidelines advise avoiding this combina-
on unless further data establish the safety and efficacy in
tients with reduced GFR (256).
ipid-Lowering Therapy and Risks of
cute Rejection Risk and Graft Loss
fter Transplantation
everal clinical trials have reached conflicting conclusions
out the effects of statin therapy on acute rejection after
dney transplantation. The earliest randomized trials of
atins for prevention of acute rejection in renal allograft
cipients reported absolute risk reductions of 30% to 40% in
e statin arms (236,247). Notably, these studies were smalld characterized by unusually high acute rejection rates in
e control groups. Three subsequent larger trials found no
sociation of statin therapy with rejection risk (238–240).
There are limited data on the relationship of dyslipidemia
erapy with preservation of allograft function after kidney
ansplantation. In the ALERT trial, there was no difference
the predefined, secondary composite endpoint of graft loss,
ubling of serum creatinine concentration, and decline in
FR in patients receiving fluvastatin compared with placebo
27,257). A large observational cohort study of first-time
nal allograft recipients in 1993 to 2000 found that statin use
as associated with improved patient survival but no signif-
ant difference in allograft survival (adjusted HR, 0.86; 95%
I, 0.55 to 1.04) (246).
ecommendation
Consistent with the recommendations of the NKF/
KDOQI Clinical Practice Guidelines for Managing
Dyslipidemias in Kidney Transplant Patients, it is
reasonable to pursue an LDL cholesterol goal of less
than 100 mg/dL in kidney transplant recipients with-
out known CAD (Class IIa; Level of Evidence B).
These guidelines parallel recommendations of the ATP III
r higher-risk members of the general population without
tablished coronary heart disease (198) and have been
corporated in the 2009 “KDIGO Clinical Practice Guideline
r the Care of Kidney Transplant Recipients” (258).
ecommendations
When therapeutic lifestyle change alone is insufficient
to achieve LDL goals, it is reasonable to initiate statin
therapy in transplanted patients with LDL cholesterol
levels above 100 mg/dL (Class IIa; Level of Evidence B).
Extrapolating from the ATP III and NKF/KDOQI
guidelines, it is reasonable to initiate therapy to reduce
non-HDL cholesterol to less than 130 mg/dL among
kidney transplant recipients with LDL less than 100
mg/dL, triglyceride levels above 200 mg/dL, and non-
HDL cholesterol above 130 mg/dL (Class IIa; Level of
Evidence B).
This pattern of dyslipidemia is managed with therapeutic lifestyle
anges, including moderation of alcohol intake, regular exercise,
oking cessation, and control of body mass and glycemia, ideally
der the guidance of a dietician experienced in the care of kidney
ansplant recipients. If further intervention is needed, a statin is
commended for patients not already receiving a statin for treat-
ent of elevated LDL cholesterol.
ecommendations
Consistent with the NKF/KDOQI guidelines, for pa-
tients who do not achieve goals with statins, it is
reasonable to discontinue the statin and replace it with
a fibrate. As noted, the 2004 KDOQI guidelines stated
that ezetimibe should probably not be used in the
transplantation setting until its safety has been estab-
lished (Class IIa; Level of Evidence C).
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July 31, 2012:434–80 Cardiac Disease Evaluation and Management Among Transplantation Candidatesble 10. Summary of Published Randomized Clinical Trials of Statin Therapy in Kidney Transplantation Recipients
rial Authors, Year
Sample Size,
Donor Types Immunosuppression
Statin, mg/d, and
Comparison
Enrollment in Relation
to KT
Trial
Duration,
mo Primary Outcome Results
rtinez-Hernandez
al. (231), 1993
26, DD or LD AZA, steroids, plus
CSA in 50%
SIMV 5 versus placebo PTD 182 2 Longitudinal change in
fasting lipid levels
Significant TCHOL (18%)
and LDL reductions
(20%) at 2 mo in SIMV
group only (p0.001)
nadottir et al.
32), 1994
40, unspecified CSA, AZA, steroids SIMV 10–20 versus
placebo
PTD 182 4 Longitudinal change in
fasting lipid levels
Significant longitudinal
TCHOL (20%) and LDL
reductions (29%) and
HDL increase (9%) only
with SIMV (p0.01)
pre et al. (233),
99
51, unspecified CSA based SIMV 5 versus placebo PTD 365 3 Longitudinal change in
lipid levels
Significant longitudinal
TCHOL (22%) and LDL
reductions (32%) and
HDL increase (13%) only
with SIMV (p0.01)
nders et al. (234),
01
30, unspecified CSA based ATORV 10 versus CERIV
0.2 versus no drug
PTD 182 3 Longitudinal change in
fasting lipid levels
Significant TCHOL (30%,
33%), LDL (42%, 38%),
and TG reductions
(23%, 23%) at 3 mo
only with ATORV and
CERIV (p0.05)
ntos et al. (235),
01
67, DD or LD AZA, steroids, plus
CSA in 71%–85%
SIMV 10 versus placebo PTD 182 6 Lipid levels at 1, 3,
and 6 mo
Significantly lower
TCHOL (22%) and LDL
(35%) at 6 mo with
SIMV versus placebo
igent et al. (195),
05
133, unspecified
(subset of 448
CKD)
Unspecified SIMV 20 versus placebo
(factorial with aspirin
versus placebo)
Unspecified 12 Nonfasting lipid levels
at 12 mo
Significantly lower
TCHOL (18%), LDL
(22%), and TG (11%) at
12 mo with SIMV versus
placebo
tznelson et al.
36), 1996
44 DD CSA, steroids PRAV 20 versus no drug PTD 7 4 BCAR Significantly lower BCAR
at 4 mo with PRAV
versus no drug (25%
versus 58%; p0.01)
ncer et al. (237),
00
57, DD or LD CSA, AZA,
steroids, plus ATG
in DD
SIMV 10 versus PRAV
20 (TCHOL 240 mg/
dL) or versus no drug
(TCHOL 240 mg/dL)
PTD 7–14 12 BCAR Significantly lower BCAR
at 12 mo with SIMV
(31%) and PRAV (25%)
versus no drug (64%;
p0.04 and p0.01)
isiske et al. (238),
01
141, DD or LD CSA, plus MMF in
85%
SIMV 10 versus placebo
versus gemfibrozil
PTD 3 3 BCAR No significant difference
in BCAR at 3 mo with
SIMV (28%), gemfibrozil
(28%), or placebo (23%)
ldaas et al. (239),
01
363, DD or LD CSA, steroids,
AZA
FLUV 40 versus placebo After transplantation 3 Steroid-treated
rejection
No difference in rejection
at 3 mo (47.3% versus
47.8%; p0.92)
hu et al. (240),
01
65 LD CSA, AZA, steroids LOV 20 versus placebo PTD 5 3 BCAR No significant difference
in BCAR at 3 mo (15%
versus 19%)
ron et al. (241),
08
57 (of 89
randomized),
unspecified
CSA, MMF,
steroids
FLUV 80 versus placebo At transplantation 6 Progression of allograft
mean intimal arterial
volume fraction, from
pre-implant to 6-mo
biopsies
No difference in primary
outcome; significantly
lower transplantation
vasculopathy with FLUV
in secondary analysis
(7% versus 33%;
p0.02)
usberg et al.
42), 2001
40 DD CSA, steroids FLUV 40 versus placebo PTD 182 6 Longitudinal change in
ultrasonographic
measures of
vasodilation
Significant increase in
brachial artery flow-
mediated vasodilation at
6 mo only with FLUV
fan et al. (243),
02
47, unspecified CSA, steroids PRAV 20 versus
low-fat diet
PTD 365 12 Longitudinal change in
ultrasonographic
measures of carotid
atherosclerosis
Significant reductions in
intima-medial thickness
and plaque number at
12 mo with PRAV (48%
and 54%, versus
unspecified control
proportions)(Continued)
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Cardiac Disease Evaluation and Management Among Transplantation Candidates July 31, 2012:434–80Consistent with NKF/KDOQI guidelines, given the
risks of pharmacological therapy to raise HDL (in the
absence of high LDL or high triglycerides), it is not
recommended to initiate such therapy in patients with
kidney disease (Class III; Level of Evidence B).
Lipid-lowering therapy specifically for the goals of
preventing acute rejection or preserving allograft func-
tion is not recommended (Class III; Level of Evidence B).
iver Transplantation Candidates
he goals of cardiovascular assessment in liver transplanta-
on candidates are to 1) determine whether a patient can be
pected to survive the operation and immediate postopera-
ve period and 2) to determine whether a patient has such
vere cardiopulmonary disease that transplantation would be
tile and an inappropriate use of a scarce donor organ.
There are fundamental differences between renal and liver
ansplantation candidates that have a major impact on the
eoperative cardiovascular risk assessment. Diabetes melli-
s with diffuse cardiovascular disease is far less common in
ver transplantation candidates than in renal transplantation
ndidates. Most patients with cirrhosis have glucose intol-
ance and are often labeled as “diabetic”; however, very few
ve retinopathy, nephropathy, vascular disease, or a family
story of diabetes mellitus. Thus, the overall risk of CAD
d diffuse vascular disease is far lower in candidates for liver
ansplantation than among patients who are candidates for
nal transplantation. When present in liver transplantation
ndidates, diabetes mellitus is often accompanied by various
grees of obesity.
Hypertension also is far less common in patients with
d-stage liver disease (ESLD) compared with patients with
SRD. Patients with cirrhosis and portal hypertension often
velop a hyperdynamic circulation with extremely low
ripheral vascular resistance and a compensatory increase in
ble 10. Continued
rial Authors, Year
Sample Size,
Donor Types Immunosuppression
Statin, mg/d, and
Comparison
sch et al. (244),
03
26, DD CSA, steroids FLUV 40 versus place
berg et al. (245),
03
75, unspecified CSA, AZA, steroids FLUV 40 versus place
ldaas et al. (227),
03
2,102, DD or LD CSA based FLUV 40 versus place
ATG indicates antithymocyte globulin; ATORV, atorvastatin; AZA, azathioprine;
D, chronic kidney disease; CSA, cyclosporine; DD, deceased donor; FLUV, flu
L, low-density lipoprotein; LOV, lovastatin; MI, myocardial infarction; MMF, m
k; SIMV, simvastatin; TCHOL, total cholesterol; and TG, triglycerides.rdiac output (259). Blood pressure in most patients is cormal or low. Thus, the need for pretransplantation treat-
ent of hypertension is unusual.
Several cardiopulmonary problems are distinctly common
ong or unique to liver transplantation candidates. These
clude pulmonary hypertension and the hepatopulmonary
ndrome, defined as hypoxia from intrapulmonary shunts in
tients with cirrhosis and portal hypertension.
valuation for CAD in
iver Transplantation Candidates
he reduced patient survival among orthotopic liver trans-
ant recipients 60 years of age has been associated with
nhepatic causes of infection, neurological events, and
rdiac events (278). The prevalence of CAD in patients with
SLD is equal to or greater than the incidence in the normal
pulation, particularly in patients with diabetes mellitus with
rrhosis, ranging from 2.5% to 27% (279–283).
Older reports suggested a high risk of postoperative mor-
lity and morbidity in patients with CAD who undergo liver
ansplantation. For example, 1 small retrospective study
ported a 50% postoperative mortality in patients with CAD
ho underwent liver transplantation (284). As a result, many
ansplantation centers perform myocardial stress testing in
ver transplantation candidates with traditional CAD risk
ctors. Most centers use pharmacological stress with dipy-
damole, dobutamine, or adenosine because many liver
ansplantation candidates are too debilitated to complete
equate exercise testing. Fewer than 10% of these tests are
sitive for provocable ischemia (282). Furthermore, there is
poor correlation between the abnormalities noted, angio-
aphic findings, and postoperative complications resulting
om CAD (282,285,286). In a series of 772 consecutive liver
ansplantation candidates who underwent MPS at 1 center,
0 were thought to be at low risk, 36 at intermediate risk, 17
high risk, and 9 had incomplete studies (287). All patients
ollment in Relation
to KT
Trial
Duration,
mo Primary Outcome Results
182 36 Longitudinal change in
ultrasonographic
measures of arterial
distensibility and
vasodilation
Significant increase in
brachial flow-mediated
vasodilation at 36 mo
only with FLUV; no
change in other
outcomes in either
group over time
2 3 Laser Doppler
flowmetric measures
of endothelial function
No between-group
differences
182 61 (mean) Composite of cardiac
death, nonfatal MI, or
coronary intervention
Nonsignificant reduction
in composite event rate
with FLUV (RR, 0.83;
95% CI, 0.64 to 1.06)
iopsy-confirmed acute rejection; CERIV, cerivastatin; CI, confidence interval;
; HDL, high-density lipoprotein; KT, kidney transplantation; LD, living donor;
olate mofetil; PRAV, pravastatin; PTD, post-transplantation day; RR, relativeEnr
bo PTD
bo PTD
bo PTD
BCAR, b
vastatin
ycophennsidered to be at high risk on the basis of stress imaging
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July 31, 2012:434–80 Cardiac Disease Evaluation and Management Among Transplantation Candidatesderwent coronary angiography. A total of 26 patients with
sitive MPS and angiographic evidence of CAD were
nied transplantation; however, CAD was the sole reason for
nial in only 7 patients. A total of 291 patients subsequently
derwent transplantation. In this group, 18 (6.2%) had an
termediate- or high-risk MPS, only one of whom had a
story of CAD. After a median follow-up of 25 months, 10
tients had a total of 13 postoperative or subsequent coro-
ry events: 5 within 30 days and 8 within the first postop-
ative year. All 5 patients with coronary events within the
rst 30 postoperative days had low-risk preoperative MPS.
hus, more recent studies suggest a lower incidence of CAD
ong liver transplantation candidates and a far lower risk of
stoperative complications than was found in prior studies.
With respect to the accuracy of noninvasive testing modal-
ies for CAD among liver transplantation candidates, single-
oton emission computed tomography perfusion imaging
monstrated a poor sensitivity and specificity for detecting
AD in liver transplantation candidates in 1 study (285). DSE
ay be used to screen low-risk liver transplantation candi-
tes for CAD (281). The prevalence of CAD among 80 liver
ansplantation candidates evaluated by DSE was 5% and was
sociated with diabetes mellitus. DSE was positive in 7.5%
patients and had a high sensitivity and specificity for CAD
this cohort, but the number of patients studied was small.
study of coronary artery calcium scores in 101 liver
ansplantation candidates found an elevated coronary artery
lcium score in 74% of asymptomatic patients (288), with
.6% having scores in the moderate-risk range (100, or
2% predicted annual risk of cardiac events) and 19.8%
ving scores in the high-risk range (400, or 3% to 5%
edicted annual risk of cardiac events) (289).
There is considerable concern about the efficacy and
st-effectiveness of the screening strategy used for CAD
entification before liver transplantation. One particular
ncern is that the vasodilated state of many liver transplan-
tion candidates lends poorly to the characteristics of some
armacological agents used for MPS (285) such as adeno-
ne or dipyridamole stress-perfusion studies.
The 2005 “AASLD Practice Guidelines: Evaluation of the
atient for Liver Transplantation” (260), include an opinion-
sed recommendation that “chronic smokers, patients over the
e of 50, and those with a clinical or family history of heart
sease or diabetes should undergo evaluation for CAD.” Based
cohort or case-control analytic studies, the guidelines also
ate that “DSE appears to be an effective screening test in this
tting; however, positive test results should be confirmed with
rdiac catheterization.” Information on the extent of CAD may
lp risk stratify the patient and better define the patient’s
ndidacy for liver transplantation (283).
Cardiac catheterization may be performed despite coagu-
pathy in patients with ESLD, although at increased risk of
eeding complications. Sharma et al. (290) reported that 88
tients with ESLD undergoing cardiac catheterization had
wer baseline hemoglobin and higher international normal-
ed ratio and serum creatinine levels than matched control
bjects. Patients with ESLD had a higher rate of vascular
mplications (5.7% pseudoaneurysms) than control subjects
%) and higher rates of requirements for red cell transfusion al6% versus 4%; p0.008), fresh-frozen plasma (51.7%
rsus 1.2%; p0.001), and platelet transfusions (48.3%
rsus 1.2%; p0.001). Major bleeding with angiography
curred in 14.8% of the ESLD group versus 3.7% of
atched control subjects.
ecommendations
Noninvasive stress testing may be considered in liver
transplantation candidates with no active cardiac con-
ditions on the basis of the presence of multiple CAD
risk factors regardless of functional status. Relevant
risk factors among transplantation candidates include
diabetes mellitus, prior cardiovascular disease, left
ventricular hypertrophy, age greater than 60 years,
smoking, hypertension, and dyslipidemia. The specific
number of risk factors that should be used to prompt
testing remains to be determined, but the committee
considers 3 or more to be reasonable (Class IIb; Level
of Evidence C).
It may be reasonable for each program to identify a
primary cardiology consultant for questions related to
potential liver transplantation candidates (Class IIb;
Level of Evidence C).
anagement of Flow-Limiting CAD in
iver Transplantation Candidates
arly reports suggested an unacceptably high mortality and
orbidity associated with liver transplantation in patients with
ncomitant CAD. Plotkin (284) reported 32 patients with CAD
ho underwent liver transplantation. Overall 1- to 3-year mor-
lity was 50%. Twenty patients with prior CABG had 50%
ortality and 80% morbidity. The 9 patients with medically
eated CAD and had 56% mortality after transplantation.
CABG surgery is associated with high morbidity and
ortality in patients with ESLD. In early reports, CABG in
SLD patients was associated with 30% to 40% mortality and
gnificant morbidity in 70% to 100% (291,292). A more
cent report of 18 patients with Child class A (n13), B
4), and C (n1) cirrhosis undergoing CABG suggested
tter in-hospital survival of 94% and a major complication
equency of 39% in patients with Child class A and 80% in
tients with Child class B/C cirrhosis. A case series of 27
ABG surgeries in patients with cirrhosis reported 26%
erative mortality (Child class A, 11%; B, 18%; C, 67%)
93). One-year survival including the in-hospital period was
% in Child class A, 45% in class B, and 16% in class C
tients. The authors concluded that, when necessary, CABG
n be performed in patients with cirrhosis and that the Child
assification predicted in-hospital and 1-year mortality.
There are also several reports of combined CABG and liver
ansplantation. Axelrod et al. (294) reported combined CABG
d orthotopic liver transplantation in 5 patients with severe
vessel CAD. There were no interoperative deaths, and com-
ned graft and patient survival at 35 months was 80% (4 of 5;
patient died of recurrent hepatitis C and liver failure).
Thus, the available studies show that significant CAD mayter suitability for liver transplantation. Patients with Child class
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Cardiac Disease Evaluation and Management Among Transplantation Candidates July 31, 2012:434–80liver failure can probably undergo CABG if indicated but with
gher risks of mortality and morbidity than in patients without
er failure. There is no information in the literature about the
tcomes of PCI in patients with CAD and ESLD. However, it
s been suggested that symptomatic, medically refractory
gina in liver transplantation candidates should be treated with
CI (preferably BMS and limited dual antiplatelet therapy).
here are no clinical data to support this recommendation, but it
not unreasonable given the lack of studies.
Acute coronary syndromes in liver transplantation candi-
tes should probably be treated with PCI per the “2011
CCF/AHA Focused Update Incorporated Into the ACC/
HA 2007 Guidelines for the Management of Patients With
nstable Angina/Non–ST-Elevation Myocardial Infarction”
40), taking into account the increased bleeding risk from
tiplatelet agents. Cardiac surgery can be performed after
ver transplantation with acceptable morbidity and mortality,
reported in a series of 15 patents from Baylor (295). This
ries reported no early deaths, 20% minor complications,
d no rejection episodes. At a mean of 26.5 months of
llow-up, 13.3% had died and 25% had recurrent angina.
ecommendation
Liver transplantation candidates who have an LVEF
less than 50%, evidence of ischemic left ventricular
dilation, exercise-induced hypotension, angina, or de-
monstrable ischemia in the distribution of multiple
coronary arteries should be referred to a cardiologist
for evaluation and long-term management according
to ACC/AHA guidelines for the general population
(Class I; Level of Evidence B).
valuation for Pulmonary Hypertension
Liver Transplantation Candidates
ulmonary arterial hypertension has been increasingly recog-
zed as a cardiovascular complication among patients with
SLD. An earlier study that linked the 2 disease states based
a consecutive series of 17,901 autopsies found a preva-
nce of biopsy-proven pathological changes consistent with
lmonary arterial hypertension in 0.13% of all patients but a
fold higher prevalence (0.73%) among patients with hepatic
rrhosis (261). More recent studies have used echocardio-
aphic Doppler techniques to identify the presence of ele-
ted PASP. One consecutive series of 83 patients with
patic cirrhosis reported a 20% prevalence of pulmonary
pertension (defined as PASP 30 mm Hg) compared with
in healthy volunteers (262). Confirmation by right heart
theterization was available in this study.
The presence of severe pulmonary hypertension is associ-
ed with a marked decrease in survival among liver trans-
antation candidates and transplant recipients (263–266). For
ample, in a retrospective study of 1,205 liver transplant
cipients, 3-year mortality rose in a graded manner among
ose with absent (PASP 30 mm Hg), mild (31 to 44 mm Hg),
oderate (45 to 59 mm Hg), and severe (60 mm Hg)
lmonary hypertension (263). Two-dimensional and Doppler
hocardiography has been shown in most studies to be anfective screening tool for pulmonary hypertension in liver
ansplantation candidates (267–270). Because of the high prev-
ence of pulmonary hypertension in liver transplantation can-
dates and adverse prognostic implications of severe disease, it
prudent to perform echocardiography in every potential liver
ansplantation candidate. Although it has been shown to be a
nsitive screening tool, potential technical pitfalls may lead to
underestimation or overestimation of the severity of disease
71,272). In addition, common echocardiographic techniques
e used to estimate the PASP, whereas the severity and
eatment of pulmonary hypertension are generally based on the
ean pulmonary artery pressure, pulmonary capillary wedge
essure, and pulmonary vascular resistance. Although these param-
ers can be derived with echocardiography (273), the proposed
ethods are less well validated and adopted in clinical practice.
hus, moderate and severe pulmonary hypertension detected on
hocardiography should be confirmed by right heart catheter-
ation (267,268).
Echocardiography with agitated saline contrast can also be
ed to detect intrapulmonary arteriovenous shunt, which is a
mmon finding in patients with ESLD, with an estimated
evalence of 17% and 47% (274). This finding is an
portant component of hepatopulmonary syndrome, defined by
e presence of chronic liver disease, significant hypoxemia, and
trapulmonary shunt. Liver transplantation is considered to be
e only effective treatment for this condition in most patients
74). Microbubbles that appear late (after a time delay of 4 to
cardiac cycles) in the left side of the heart after agitated saline
jection into the venous system are consistent with the diagno-
s. Immediate or early shunting is more consistent with an atrial
ptal defect or patent foramen ovale. If diagnostic questions
main after performance of a transthoracic study, a transesoph-
eal echocardiogram can provide increased sensitivity (51%
rsus 32%; p0.001) and direct visualization of bubbles
tering the left atrium from the pulmonary veins rather than
ossing the interatrial septum (275).
ecommendation
It is reasonable to perform resting echocardiography
in patients who are potential liver transplant recipients
for the purpose of identifying pulmonary hypertension
and/or intrapulmonary arteriovenous shunt (Class IIa;
Level of Evidence B).
There is no consensus or guideline on the threshold value
PASP measured by Doppler echocardiography that should
used to trigger further invasive testing with right heart
theterization. The presence of severe pulmonary hyperten-
on (PASP 60 mm Hg) on noninvasive testing has most
early been associated with adverse outcomes in the liver
ansplantation population. Because of the margin of error of
e measurement, a cutoff value of 45 mm Hg may be
asonable until more data are available.
ecommendation
If right heart catheterization confirms the presence of
significant pulmonary arterial hypertension (as defined
by mean pulmonary artery pressure >25 mm Hg,
Ta
1.
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July 31, 2012:434–80 Cardiac Disease Evaluation and Management Among Transplantation Candidatesble 11. Proposed Randomized Controlled Trials in Kidney and Liver Transplantation Candidates
Screening for obstructive CAD among potential transplantation candidates
Target population: potential candidates for deceased and living donor kidney and/or liver transplantation
Intervention: randomized comparison of 4 approaches to the preoperative cardiovascular evaluation: 1) cardiac catheterization for all candidates, including
fractional flow reserve measurement in indeterminate lesions, 2) noninvasive stress testing for all patients, 3) noninvasive stress test based on presence of
3 or more cardiac risk factors,* 4) ACC/AHA cardiac evaluation and care algorithm for noncardiac surgery (7)
Primary outcome
MACEs
Timing: pretransplant, peritransplant, and 1, 5, and 10 y post-transplant
Secondary outcomes
Access to transplantation
Cost-effectiveness
Optimal preoperative treatment strategy for 1- or 2-vessel CAD (excluding left main or proximal LAD)
Target population: asymptomatic potential kidney and/or liver transplantation candidates (without active cardiac conditions) referred for cardiac catheterization
because of the presence of ischemia on noninvasive testing in whom 1- or 2-vessel CAD is identified at cardiac catheterization, with fractional flow reserve
in indeterminate lesions
Intervention: randomized comparison of PCI versus optimal medical therapy
Primary outcome
MACEs
Timing: pretransplant, peritransplant, and 1, 5, and 10 y post-transplant
Secondary outcomes
Access to transplantation
Waitlist mortality
Cost-effectiveness
Optimal surveillance strategy for obstructive CAD on the waitlist
Target population: kidney and/or liver transplantation candidates with multiple CAD risk factors* actively listed for deceased donor transplantation
Intervention: randomized comparison of 4 strategies for repeat noninvasive stress testing: 1) annual, 2) every 2 years, 3) every 3 years, or 4) only based on a
change in symptoms
Primary outcome
MACEs
Timing: pretransplant, peritransplant, and 1, 5, and 10 y post-transplant
Secondary outcomes
Access to transplantation
Waitlist mortality
Cost-effectiveness
Other cardiac conditions
4a. Valvular heart disease
Target population: potential kidney and/or liver transplantation candidates with asymptomatic severe aortic stenosis (aortic valve area 1.0 cm2)
Intervention: randomized comparison of standard care (per the ACC/AHA guidelines for the management of valvular heart disease [102]) versus
pretransplantation valve replacement.
Primary outcome
MACEs
Timing: pretransplant, peritransplant, and 1, 5, and 10 y post-transplant
4b. Pulmonary hypertension
Target population: potential kidney and/or liver transplantation candidates with pulmonary arterial hypertension confirmed on right heart catheterization
(mean pulmonary artery pressure 25 mm Hg, pulmonary capillary wedge pressure 15 mm Hg, pulmonary vascular resistance 3 Wood units)
Intervention: randomized comparison of vasodilator strategies: endothelin receptor blockers versus phosphodiesterase inhibitors
Primary outcome
MACEs
Timing: pretransplant, peritransplant, and 1, 5, and 10 y post-transplant
Secondary outcomes
Access to transplantation
Waitlist mortality
Change in functional capacity, defined by the 6-min walk test(Continued)
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nary vascular resistance of >3 Wood units) in the
absence of an identified secondary cause (e.g., obstruc-
tive sleep apnea, left heart disease), referral to a
consultant with expertise in pulmonary arterial hyper-
tension management and advanced vasodilator thera-
pies is reasonable (Class IIb; Level of Evidence C).
Despite the adverse prognostic implications of pulmonary
pertension, successful presurgical treatment of pulmonary
pertension is associated with excellent survival after liver
ansplantation (265,266). It has been shown that many
tients can discontinue vasodilator therapy within months
ter liver transplantation. Every patient with severe pulmo-
ry hypertension who is otherwise a good candidate for liver
ansplantation should be considered for treatment with va-
dilator therapy. Patients who have an excellent response to
eatment have outcomes after liver transplantation compara-
e to those of other transplantation candidates (276,277).
edical Management of Cardiovascular
isk in Liver Transplantation Candidates
reoperative medical management of hypertension, lipid
sturbances, and atherosclerotic risk in liver transplantation
ndidates differs considerably from that of renal transplan-
tion candidates. Because of the hyperdynamic circulation
at develops in most patients with ESLD with portal hyper-
nsion, preoperative or postoperative hypertension is an
usual complication in most liver transplantation candidates.
ost liver transplantation candidates with hypertension have
trinsic renal disease as a comorbid condition. All of the
odern antihypertensives appear to be safe in ESLD; thus,
ose few patients who are hypertensive can be managed in a
shion similar to that used for renal transplantation candi-
tes. Patients with large esophageal varices benefit particu-
rly from nonselective beta-blockers (propranolol or na-
lol) to reduce the risk of variceal hemorrhage (296). A
trospective study of 413 liver transplant recipients at 1 center
und that the 27% of the sample receiving propranolol or
etoprolol in the perioperative period experienced a marked
duction in the adjusted odds of nonfatal MI or death within 30
ys (adjusted OR, 0.20; 95% CI, 0.07 to 0.59) compared with
beta-blocker use (297). However, additional study, ideally in
randomized trial, is needed before conclusions can be made
ecifically about the use of beta-blockers for cardioprotection
ble 11. Continued
Medical management of cardiovascular risk
Target population: kidney and/or liver transplantation candidates
Intervention: aspirin versus placebo for primary prevention of MACEs
Primary outcome
MACEs
Timing: pretransplant, peritransplant, and 1, 5, and 10 y post-transp
ACC/AHA indicates American College of Cardiology/American Heart Association
rdiac events; and PCI, percutaneous coronary intervention.
*CAD risk factors are as defined under “Summary and Recommendations Rega
rdiac Conditions.”fore liver transplantation. Tecommendation
It is reasonable to initiate nonselective beta-blockers in
liver transplantation candidates with large esophageal
varices (Class IIa; Level of Evidence B).
Because of the generally short duration of the waiting time
fore liver transplantation, control of lipid abnormalities and
edical management of atherosclerotic risk factors are not
gh priorities in the pretransplantation management of most
ver transplantation candidates. Furthermore, the lipid abnor-
alities that develop in patients with severe cholestatic liver
seases have not been shown to be associated with an
creased risk of coronary events (298). In addition, because
any liver transplantation candidates have a coagulopathy
ith prolonged prothrombin times, thrombocytopenia from
persplenism, and esophageal and gastric varices, any form
anticoagulation is generally avoided unless or until the
tient has well-documented CAD. Furthermore, any non-
eroidal medication (including aspirin) is generally avoided
cause of the risks of gastric irritation, bleeding, and
acerbation of renal dysfunction in patients with ESLD.
Prospective studies on optimal screening strategies for the
esence of CAD and the indications, timing, and outcomes
interventional therapy in patients with ESLD are lacking
d much needed.
onclusions
atients with ESRD or ESLD are at increased risk for cardiac
ents compared with the general population. Cardiovascular
sease remains the most common cause of death in solid-
gan transplant recipients, with the highest rates occurring
mediately after transplantation. This increased cardiovas-
lar risk may be related to traditional and nontraditional risk
ctors and is associated with a somewhat different patho-
ysiology compared with the pathophysiology in patients
ithout end-stage organ disease. The presence of symptoms
cardiovascular disease is an important prognostic marker
at warrants cardiac evaluation. Noninvasive methods for
reening for CAD have prognostic value for mortality but
perfect sensitivity and specificity for detecting angiographi-
lly defined CAD in patients with kidney or liver failure.
ssociations of CAD by angiography with subsequent survival
e also inconsistent, likely because many plaque ruptures
oducing MI are not localized to sites of angiographic stenosis.
oronary artery disease; LAD, left anterior descending; MACEs, major adverse
ninvasive Stress Testing in Kidney Transplantation Candidates Without Activelant
; CAD, c
rding Nohe efficacy and best methods of myocardial revascularization
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ong patients with CKD or chronic liver disease. At this time,
ere is no strong evidence for or against routine cardiac
reening of asymptomatic transplantation candidates. More
idence is required, ideally from randomized clinical trials, to
ide strategies for pretransplantation cardiac risk assessment in
tential kidney or liver transplantation candidates and to opti-
ize risk factor management before, during, and after transplan-
tion. Clinical trials proposed by the work group are provided in
able 11.
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